



Go Green, Go Online!  
**JDDonline.com**

As part of the JDD green initiative, starting in 2009, the author and subject indexes will be published exclusively online. In previous years these have been printed in the December Issue, but for your convenience and for environmental consciousness, the indexes will now be available electronically.

## 2009 SUBJECT INDEX

Letters after article titles refer to the following: **APT** = Aesthetic Practice Trends; **CP** = Clinical Pearl; **CR** = Case Reports;

**CTR** = Clinical Trial Review; **FO** = Focus On; **LCN** = Laser and Cosmetic News; **LR** = Literature Review; **NND** = No-Nonsense Dermoscopy; **NVR** = News, Views, and Reviews; **PP** = Pipeline Previews; **SCF Update** = Skin Cancer Foundation Update; **SP** = Schools of Pharmacology; **WU** = Washington Update

### A

- Abatacept**, safety and efficacy in subjects with chronic urticaria after inadequate response to antihistamine therapy (CTR), 601
- Abdomen**  
 pulsed dye laser and nonablative laser for abdominoplasty scars (CTR), 312  
 skin rejuvenation and wrinkle reduction using a fractional radiofrequency system, 259
- Abscess**  
 isotretinoin-associated perioral abscess (CR), 1034  
 wound packing after superficial skin abscess drainage (CTR), 503
- Acai berry**, s5 (June)
- Acanya™ gel**, FDA approval of (PP), 194
- N-Acetylglucosamine**, s10 (June)
- Acid peel**, and laser for melasma (CTR), 425, 686, 887
- Acitretin (U0279)**, and injectable biologic combination therapy for psoriasis (CTR), 686, 888, 963, 1057
- Acne agminata**, clofazimine for, 846
- Acne vulgaris**  
 acne quality of life and patient satisfaction after treatment with tretinoin pump, 1080  
 Aesthera announces innovations for (PP), 498  
 ALA PDT in photoaging, vitiligo and, 562  
 approval of Epiduo® acne gel (PP), 92, 194  
 BenzEfoam Emollient Foam for body acne (PP), 1150  
 benzoyl peroxide wash for (PP), 310  
 blue light PDT in African-American patient (CR), 669  
 comparative study of tolerability of two combination therapies for (CTR), 597, 961  
 comparison of novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin for, 812  
 dapsone gel and tazarotene cream versus tazarotene cream monotherapy for facial acne (CTR), 421, 499, 597  
 dapsone gel and tretinoin gel versus tretinoin gel monotherapy for facial acne (CTR), 421  
 development and optimization of fixed combination of clindamycin and benzoyl peroxide aqueous gel for, 634  
 efficacy and safety of CIP-isotretinoin for recalcitrant nodular acne (CTR), 1054  
 efficacy and safety of two topical combination regimens for, 624  
 evaluation of tolerability of two topical drug products for (CTR), 1054  
 FDA approval of Acanya™ gel for (PP), 194  
 fixed combination of clindamycin phosphate and low concentration benzoyl peroxide aqueous gel for, 736  
 increasing efficacy and tolerability of benzoyl peroxide-based treatments for, 657  
 liposomal methylene blue hydrogel for selective PDT of, 983  
 methyl aminolevulinate PDT in patients with skin type V or IV with (CTR), 499, 597, 961  
 oral contraceptive containing 3 mg drospirenone plus 20 mg ethinylestradiol for, 837  
 pathogenesis of, 615  
 PDT in treatment of (CTR), 499, 780  
 Perrigo and Sulfacetamide Sodium Topical Suspension (PP), 498  
 photopneumatic therapy for, 239  
 plant-based dietary intervention for (CTR), 780  
 recall of topical acne cream (PP), 92  
 RegeneCare® wound gel for rash in patients receiving cetuximab or other epidermal growth factor receptor inhibitor therapy for cancer (CTR), 1054  
 review of PDT for, 1010  
 safety and efficacy of Botox for (CTR), 195, 421  
 safety and efficacy of drospirenone and ethinyl estradiol (YAZ) versus placebo in (CTR), 499, 961  
 simultaneous use of fixed topical antibiotic/benzoyl peroxide combination and topical retinoid for (CR), 1126  
 SmartSkin™ fractional laser for photodamage and acne scars, s4 (November)  
 study of treatment in children (CTR), 780  
 superficial chemical peels for, 803  
 tea tree oil for (NVR), 494  
 tolerability of clindamycin/tretinoin gel versus tretinoin microsphere gel and adapalene gel for, 383  
 topical 2% green tea lotion for, 358  
 topical azelaic acid 15% gel combined with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy for, 639  
 topical retinoids and acne "flares," 799  
 treatment in children aged 9 to 11 (CTR), 961  
 tretinoin microsphere gel pump versus tazarotene cream for facial acne, 650  
 2940 nm fractional photothermolysis laser for  
 acne scarring, 978  
 use of low-fluence 1064 nm Nd:YAG laser in female with contraindications to systemic anti-acne therapy (CR), 1025
- Actinic keratoses (AK)**  
 ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 1055  
 beyond a decade of 5% imiquimod topical therapy, 467  
 imiquimod for (PP), 310  
 long-term effects of imiquimod and diclofenac for (CTR), 1054  
 methyl aminolevulinate PDT in subjects with field AK, BCCs, or Bowen's disease (CTR), 195, 689, 965  
 phase II AK study in organ transplant patients (CTR), 1055  
 phototherapy with topical retinoid versus phototherapy alone for AK (CTR), 195, 885, 1054  
 safety and effectiveness of AK treatment following cryosurgery (CTR), 885  
 sequential PDT and imiquimod 5% cream for, 35  
 topical calcipotriol for, 451  
 topical imiquimod cream combined with cryotherapy for (CTR), 885  
 topical perillyl alcohol for sun damaged skin and AK (CTR), 195, 885, 1055  
 topical sulindac combined with hydrogen peroxide for, 29
- Acyclovir**, hydrocortisone/acyclovir cream approved by FDA (PP), 959
- Adalimumab**  
 anti-TNF agents for psoriasis, 546  
 biologic survival, 329  
 clinical update on antitumor necrosis factor agents for psoriasis, 147  
 for disseminated granuloma annulare (CR), 169  
 for hidradenitis suppurativa (CR), 181  
 management of psoriasis in the age of biologics, s2 (September), s5 (September)  
 for palmoplantar psoriasis (CR), 1136
- Adapalene**  
 approval of Epiduo® acne gel (PP), 92, 194  
 comparative study of tolerability of two combination therapies for acne (CTR), 597, 961  
 evaluation of tolerability of two topical drug products for facial acne (CTR), 1054  
 tolerability of clindamycin/tretinoin gel versus

- tretinoin microsphere gel and adapalene gel for acne, 383
- Adolescents.** See Pediatric dermatology
- Adrenal function,** and use of intralesional triamcinolone acetonide in alopecia areata (CTR), 685, 886
- AEB071,** dose finding study assessing psoriasis area and severity index (CTR), 781
- Afamelanotide** (NVR), 772
- Aging skin.** See Cutaneous aging
- AIN457,** efficacy of single dose of three dose levels in psoriasis (CTR), 88, 500, 686
- Albaconazole,** efficacy and safety of 4 oral dose regimens for distal subungual onychomycosis (CTR), 89
- Alclometasone**  
alclometasone dipropionate cream (PP), 883  
topical, 1093
- Aldara.** See Imiquimod 5% cream
- Alefacept**  
biologic survival, 329  
clinical update on T-cell modulators and investigational agents for psoriasis, 230  
management of psoriasis in the age of biologics, s2 (September), s5 (September)  
for psoriasis, s6 (May, T Cell Agents)  
safety and efficacy in atopic dermatitis (CTR), 422
- Alemtuzumab,** therapies for cutaneous T-cell lymphoma (NVR), 1142
- Aleosisin,** s10 (June)
- Alitretinoin,** for hand eczema (PP), 193
- Allergens**  
contact allergens in children and adults (NVR), 79  
efficacy of montelukast in atopic dermatitis induced by food allergens (CTR), 598
- Alopecia**  
adrenal function and use of intralesional triamcinolone acetonide in alopecia areata (CTR), 685, 886  
alopecia areata registry and immunogenetic mechanisms (CTR), 685  
diagnosis and treatment of androgenetic alopecia (NVR), 185  
efalizumab for alopecia areata (CTR), 195  
hair regrowth after long-term efalizumab therapy for alopecia areata (CR), 758  
intralesional injections of botulinum toxin for alopecia areata of scalp (CTR), 886  
intralesional steroid injections for alopecia areata, 909  
intralesional triamcinolone acetonide for alopecia areata (CTR), 196  
intramuscular triamcinolone for (CR), 580  
spironolactone pills versus minoxidil lotion in female pattern hair loss (CTR), 196, 423, 685, 886, 1152  
treatment of androgenetic alopecia in males (CTR), 1152
- Alpha-GAL glycosphingolipids,** intratumoral injection of (CTR), 1156
- Alpha-linolenic acid,** s10 (June)
- Alpha-tocopherol,** and fluconazole for yellow nail syndrome (CR), 276
- Altanax®,** concurrent Altanax® and topical low-potency corticosteroids versus low-potency corticosteroid monotherapy for atopic dermatitis (CTR), 780, 962
- Aluminum chloride in salicylic acid gel base,** for axillary hyperhidrosis, 477
- Amcinonide,** topical, 1093
- AMG 157,** safety in atopic dermatitis (CTR), 422, 598, 781, 962, 1152
- Aminolevulinic acid (ALA)**  
ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 1055  
PDT in acne, photoaging, and vitiligo, 562  
PDT using ALA in treating patients with skin cancer (CTR), 88, 689, 965  
topical ALA in nonmelanoma skin cancer (CTR), 88
- Amlodipine,** stasis dermatitis induced by, 135
- Anatomy**  
anatomic considerations for soft tissue augmentation of the face, 13  
applied anatomy of temporal region and forehead for injectable fillers, s24 (October)
- Anesthesia/analgesia**  
calcium hydroxylapatite: safety, techniques, and pain reduction, s21 (October)  
FDA alert on topical anesthetics (PP), 310  
forced cold air and topical anesthetic cream for analgesia during botulinum toxin injections for palmar hyperhidrosis (CR), 948  
petechial and purpuric eruption induced by lidocaine/prilocaine cream (CR), 287  
transdermal bupivacaine patch for postherpetic neuralgia (CTR), 89
- Angioedema,** vitamin D levels in patients with chronic urticaria and (CTR), 889
- Angular artery,** anatomic considerations for soft tissue augmentation of the face, 13
- Anti-inflammatory agents,** for seborrheic dermatitis, 125
- Antiandrogens,** for androgenetic alopecia (NVR), 185
- Antifungal drugs**  
clobetasol propionate shampoo and antifungal shampoo in scalp seborrheic dermatitis (CTR), 501, 1057  
efficacy and safety of 4 dose regimens of oral albaconazole for distal subungual onychomycosis (CTR), 89  
efficacy of bifonazole cream versus placebo after nail ablation with urea paste (CTR), 90  
fluconazole and alpha-tocopherol for yellow nail syndrome (CR), 276  
ketoconazole for seborrheic dermatitis (CTR), 197, 501  
for seborrheic dermatitis, 125
- Antihistamines**  
for chronic urticaria (NVR), 1043  
desloratadine with levocetirizine in chronic idiopathic urticaria (CTR), 90, 601  
levocetirizine for chronic idiopathic urticaria, 243  
omalizumab in patients with chronic idiopathic urticaria who remain symptomatic with antihistamine treatment (CTR), 601, 890  
safety and efficacy of abatacept in subjects with chronic urticaria after inadequate response to antihistamine therapy (CTR), 601  
Xyzal for pruritus in atopic dermatitis (CTR), 598, 781, 962, 1152
- Antimalarials,** for chronic urticaria (NVR), 1043
- Antimicrobial drugs**  
anti-inflammatory dose doxycycline for rosacea, 664  
antibiotic selection for MRSA (CR), 281  
Bausch & Lomb and Besivance™ (PP), 884  
bicillin LA versus placebo for psoriasis unresponsive to topical medications (CTR), 687  
clindamycin and rifampicin for hidradenitis suppurativa (PP), 1050  
comparison of novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin, 812  
development and optimization of fixed combination of clindamycin and benzoyl peroxide aqueous gel for acne vulgaris, 634  
efficacy and safety of two topical combination acne regimens, 624  
FDA rejects ceftobiprole (PP), 193  
fixed combination of clindamycin phosphate and low concentration benzoyl peroxide aqueous gel for acne, 736  
IV/PO moxifloxacin for complicated skin infection (CTR), 313  
moxifloxacin-induced hypersensitivity syndrome (CR), 1031  
retapamulin versus linezolid in SITL and impetigo due to MRSA (CTR), 503, 784  
safety and efficacy of clindamycin phosphate and tretinoin gel for rosacea (CTR), 421, 597  
simultaneous use of fixed topical antibiotic/benzoyl peroxide combination and topical retinoid for acne (CR), 1127  
tolerability of clindamycin/tretinoin gel versus tretinoin microsphere gel and adapalene gel for acne, 383  
topical azelaic acid 15% gel combined with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy for, 639  
topical azelaic acid gel plus anti-inflammatory dose doxycycline or metronidazole gel in rosacea (CTR), 598  
Vibativ™ (telavancin) for skin infection (PP), 1151
- Antioxidants,** s5 (June)
- Antiphospholipid syndrome,** concurrent antiphospholipid syndrome and cutaneous sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C (CR), 870
- Antiretroviral drugs**  
autologous fat transfer for facial lipoatrophy due to, 486  
FDA warning for etravirine (PP), 1050
- Anti-tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) therapy**  
adalimumab for disseminated granuloma annulare (CR), 169  
adalimumab for hidradenitis suppurativa (CR), 181  
adalimumab for palmoplantar psoriasis (CR), 1136  
biologic survival, 329  
etanercept and U0279 combination therapy for psoriasis (CTR), 686, 888, 963, 1057  
etanercept for atopic dermatitis (CR), 873  
etanercept for pemphigus vulgaris (CR), 940  
etanercept for psoriasis (PRISTINE) (CTR), 500  
etanercept in dermatomyositis (CTR), 196, 423  
FDA finds cancer risk with TNF blockers (PP), 1050  
follow-up of psoriatic arthritis mutilans patients treated with (CR), 406  
infection in psoriasis and rheumatoid arthritis patients treated with (CR), 175  
infliximab for pemphigus vulgaris (CTR), 599  
management of psoriasis in the age of biologics, s2 (September), s5 (September)  
narrowband UVB and etanercept for psoriasis (PP), 91  
for psoriasis, 546  
for psoriasis: clinical update, 147  
Remicade in psoriasis patients with inadequate response to etanercept (CTR), 500  
safety and effectiveness of etanercept for lichen planus on oral mucosa or skin (CTR), 500  
safety and efficacy of etanercept in discoid lupus erythematosus (CTR), 424, 1155  
safety and efficacy of infliximab in palmoplantar psoriasis (CTR), 888  
study to evaluate switch from etanercept to infliximab in psoriasis (CTR), 782
- Antiviral drugs**  
concurrent antiphospholipid syndrome and

- cutaneous sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C (CR), 870
- FV-100 versus valacyclovir in herpes zoster (CTR), 785, 1056
- hydrocortisone/acyclovir cream approved by FDA (PP), 959
- phase 2b trial of EPB-348 for herpes zoster (CTR), 1056
- safety and pharmacokinetics of famciclovir in adolescents with recurrent herpes labialis (CTR), 600
- API 31510**, in topical cream for in situ cutaneous SCC (CTR), 313, 688, 964
- Apremilast**  
in atopic or contact dermatitis (CTR), 1153  
efficacy and safety in psoriasis (CTR), 87, 500  
safety study of clinical and immune effects of Phosphodiesterase-4 inhibitor in cutaneous lupus erythematosus (CTR), 424, 1154
- Arbutin**, s5 (June), s10 (June)
- Arthritis**  
follow-up of psoriatic arthritis mutilans patients treated with anti-TNF therapy (CR), 406  
infection in psoriasis and rheumatoid arthritis patients treated with antitumor necrosis factor agents and methotrexate (CR), 175
- Atopic dermatitis**  
Albolene versus Mimyx for (PP), 1150  
alitreinoin for hand eczema (PP), 193  
apremilast in atopic or contact dermatitis (CTR), 1153  
concurrent Altanax<sup>®</sup> and topical low-potency corticosteroids versus low-potency corticosteroid monotherapy for (CTR), 780, 962  
efficacy of lipid-based barrier repair formulation in pediatric patients, 1106  
etanercept for (CR), 873  
impact of treating *Staphylococcus aureus* infection and colonization on clinical severity of (CTR), 422  
induced by food allergens, efficacy of montelukast in (CTR), 598  
molecular and cellular characteristics of spongiotic dermatitis (CTR), 197  
new skin barrier cream for (CR), 1037  
safety and efficacy of alefacept in (CTR), 422  
safety of AMG 157 in (CTR), 422, 598, 781, 962, 1152  
skin concentrations following topical versus oral steroid treatment, 1076  
three times weekly tacrolimus ointment for (PP), 91  
topical nonsteroidal agent for pruritus in, 537  
topical treatment for hand dermatitis (CTR), 197  
vitamin D supplementation in children with (CTR), 963  
Xyzal for pruritus in (CTR), 598, 781, 962, 1152
- Atopiclair<sup>®</sup>**, for pruritus in atopic dermatitis, 537
- Avenanthramide extract**, s5 (June)
- Axillary hyperhidrosis**, 15% aluminum chloride in 2% salicylic acid gel base for, 477
- Azelaic acid**  
versus hydroquinone in melasma (CTR), 887  
for hyperpigmentation (NVR), 879  
for seborrheic dermatitis, 125  
topical, plus anti-inflammatory dose doxycycline or metronidazole gel in rosacea (CTR), 598  
topical azelaic acid 15% gel combined with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy for, 639
- AZ100**, following excision of keloid scars (CTR), 312, 782
- B**
- Basal cell carcinoma (BCC)**  
beyond a decade of 5% imiquimod topical therapy, 467  
efficacy and safety of GDC-0449 in advanced BCC (CTR), 502, 784, 964, 1156  
Intron-A/Aldara combination therapy for (CTR), 502  
LDE225 for skin BCC in Gorlin's syndrome (CTR), 1155  
methyl aminolevulinate PDT in subjects with field AK, BCCs, or Bowen's disease (CTR), 195, 689, 965  
nodular BCC appearing as morpheaform during Mohs micrographic surgery (CR), 163  
superficial, PDT using methyl aminolevulinate for, 992  
topical tazarotene for BCC and basal cell nevus syndrome on chest and back (CTR), 689  
topical tazarotene for BCC and basal cell nevus syndrome on face (CTR), 1155
- Becker's melanosis with atypical features**, clinicopathologic profile of, 745
- Belotero<sup>®</sup>**, safety and effectiveness in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963
- Bendamustine HCl intravenous infusion**, Treanda and toxic epidermal necrolysis (PP), 883
- Benzoyl peroxide**  
approval of Epiduo<sup>®</sup> acne gel (PP), 92, 194  
BenzEfoam Emollient Foam for body acne (PP), 1150  
comparative study of tolerability of two combination therapies for acne (CTR), 597, 961  
comparison of novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin, 812  
development and optimization of fixed combination of clindamycin and benzoyl peroxide aqueous gel for acne vulgaris, 634  
efficacy and safety of two topical combination acne regimens, 624  
evaluation of tolerability of two topical drug products for facial acne (CTR), 1054  
FDA approval of Acanya<sup>™</sup> gel for acne (PP), 194  
fixed combination of clindamycin phosphate and low concentration benzoyl peroxide aqueous gel for acne, 736  
increasing efficacy and tolerability of benzoyl peroxide-based acne treatments, 657  
recall of topical acne cream (PP), 92  
simultaneous use of fixed topical antibiotic/benzoyl peroxide combination and topical retinoid for acne (CR), 1126  
wash for acne (PP), 310
- Benzyl alcohol lotion**, for head lice (PP), 682
- Besifloxacin ophthalmic suspension** (PP), 884
- Besivance<sup>™</sup>**. See Besifloxacin ophthalmic suspension
- Betamethasone**  
clobetasol propionate 0.05% spray versus calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for psoriasis, 52  
FDA approval for betamethasone dipropionate cream, 0.05% (augmented) (PP), 92  
skin concentrations following topical versus oral steroid treatment, 1076  
topical, 1093
- Bexarotene**, therapies for cutaneous T-cell lymphoma (NVR), 1142
- Bicillin L-A**, versus placebo for psoriasis unresponsive to topical medications (CTR), 687
- Bifonazole cream**, versus placebo after nail ablation with urea paste (CTR), 90
- Bimatoprost**, for hypotrichosis of eyelashes (PP), 92
- Biomaterials**  
advanced techniques for Sculptra, s17 (April)  
advances in collagen fillers, s12 (April)  
applied anatomy of temporal region and forehead for injectable fillers, s24 (October)  
Beer Hand Scale to grade dorsal hand aging and response to treatments, s9 (April)  
Belotero<sup>®</sup> Balance PMA filing accepted (PP), 1051  
calcium hydroxylapatite: safety, techniques, and pain reduction, s21 (October)  
Canadian report on the safety and effectiveness of Evolence<sup>®</sup> Breeze<sup>™</sup>, 830  
Coapt Systems launches Hydrelle<sup>™</sup> (PP), 1051  
combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and calcium hydroxylapatite, s21 (April)  
delayed onset nodules from liquid injectable silicone (CR), 952  
dissolving collagen fillers (CR), 1140  
efficacy of lipid-based barrier repair formulation in pediatric atopic dermatitis, 1106  
FDA approves poly-L-lactic acid for nasolabial folds (PP), 959  
FDA marketing clearance for SurgiSeal (PP), 193  
filler revolution: six-year perspective, 903  
grading system for malar crease region and implications for treatment with soft-tissue augmentation products, s5 (April)  
hyaluronic acid needle-free injection for damaged and wrinkled skin (CTR), 312  
hyalurons for soft-tissue augmentation, 1086  
introduction to supplement on facial rejuvenation, s3 (April)  
lip augmentation and contour correction with collagen dermal filler, s1 (March)  
nasolabial fold filler study for people of color (CTR), 687  
new skin barrier cream for atopic dermatitis (CR), 1037  
patient satisfaction and duration of effect with PLLA, s15 (October)  
rapid absorbing gut suture versus 2-octylethylcyanoacrylate tissue adhesives in epidermal closure of linear repairs, 115  
Restylane and Perlane in correction of perioral wrinkles (CTR), 1056  
safety and effectiveness of Belotero<sup>®</sup> in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963  
safety of hyaluronic acid versus hyaluronic acid combined with lidocaine (CTR), 87  
science and art of dermal fillers for soft-tissue augmentation, 335  
stronger warning labels for fillers (PP), 194  
treatment of aging hand with Radiesse<sup>®</sup> (CR), 1121  
twelve-month labeling approval for Evolence (PP), 960  
using poly-L-lactic acid to mimic volume in multiple tissue layers, s5 (October)  
validated rating scale for management of lip fullness and aging options, s24 (April)
- Bismuth subsalicylate**, black tongue secondary to (CR), 1132
- Blepharitis**, treatment of patients with blepharitis and facial rosacea (CTR), 422
- Body contouring**  
disfiguring scarring after mesotherapy-associated *Mycobacterium cosmeticum* infection (CR), 391  
histological comparison of 1064 nm Nd:YAG and 1320 nm Nd:YAG laser lipolysis, 377  
VASER<sup>®</sup> Lipo for body contouring and fat transfer

(PP), 1050

**Botanicals**

in cosmetic dermatology, s5 (June)

for hyperpigmentation, s10 (June)

introduction to supplement on, s4 (June)

topical 2% green tea lotion for acne, 358

Zcalm™ post-laser revitalizing cream available (PP), 1052

**Botulinum toxin A**

efficacy and safety of new botulinum toxin type A in retreatment of glabellar lines, 439

FDA boxed warning for botulinum toxin products (PP), 595

forced cold air and topical anesthetic cream for analgesia during injections for palmar hyperhidrosis (CR), 948

intra-dermal injections for alopecia areata of scalp (CTR), 886

versus NT 201 for glabellar frown lines (CTR), 312

for periorbital eccrine hidrocystomas (CR), 71

for psoriasis (CTR), 686, 963

Reloxin for rhytids (PP), 497

safety and efficacy for acne (CTR), 195, 421

safety and efficacy of RT001 for lateral canthal lines (CTR), 1056

safety warnings for (PP), 959

for seborrheic dermatitis in parkinsonian patients (CTR), 197

for upper facial rhytids, patient perception of treatment outcomes, 924

**Bowen's disease**, methyl aminolevulinate PDT in subjects with field AK, BCCs or (CTR), 195, 689, 965**Bulimia nervosa**, painful parotid hypertrophy with (CR), 577**Bupivacaine**, transdermal patch for postherpetic neuralgia (CTR), 89**Burn injury**, ablative fractional laser resurfacing for treatment of third-degree burn (CR), 294**C****Calcineurin inhibitors**

for chronic urticaria (NVR), 1043

therapies for cutaneous T-cell lymphoma (NVR), 1142

**Calcipotriene**, clobetasol propionate 0.05% spray versus calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for psoriasis, 52**Calcipotriol**, topical, for AK, 451**Calcitriol**

3 µg/g ointment for psoriasis, s17 (August)

in adolescents (CTR), 782

efficacy and safety of, s9 (August)

introduction to supplement on, s3 (August)

optimizing therapy with, s23 (August)

FDA approval for Vectical (PP), 497

**Calcium hydroxylapatite**

Beer Hand Scale to grade dorsal hand aging and response to treatments, s9 (April)

combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and, s21 (April)

filler revolution: six-year perspective, 903

safety, techniques, and pain reduction, s21 (October)

science and art of dermal fillers for soft-tissue augmentation, 335

treatment of aging hand with Radiesse® (CR), 1121

**Candida antigen**, for treatment of verruca vulgaris in patient with HIV (CR), 268**Carvedilol**, hypersensitivity and (PP), 960**CC-10004 (apremilast)**

in atopic or contact dermatitis (CTR), 1153

efficacy and safety in psoriasis (CTR), 87, 500

safety study of clinical and immune effects of

Phosphodiesterase-4 inhibitor in cutaneous lupus erythematosus (CTR), 424, 1154

**Ceftobiprole**, FDA rejection of (PP), 193**Cetuximab***Malassezia* folliculitis presented as acneiform eruption after (CR), 274

Regenecare® wound gel for rash in patients receiving cetuximab or other epidermal growth factor receptor inhibitor therapy for cancer (CTR), 1054

topical pimecrolimus for cetuximab-associated eruption (PP), 1050

**Chamomile**, s5 (June)**Cheilitis granulomatosa**, clofazimine for, 846**Chemical peels**

acid peel and laser for melasma (CTR), 425, 686, 887

clinical role and application, 803

for hyperpigmentation (NVR), 879

**Chemokines**, therapies for cutaneous T-cell lymphoma (NVR), 1142**Chemotherapy**

cutaneous chronic graft versus host disease in treatment with psoralen plus UVA-bath photochemotherapy (CR), 1027

hair depigmentation during dasatinib therapy (CR), 395

paclitaxel-related photodistributed erythema multiforme (CR), 61

sorafenib-associated dyskeratotic plaque with milia (CR), 573

therapies for cutaneous T-cell lymphoma (NVR), 1142

Treanda and toxic epidermal necrolysis (PP), 883

**Children**. See Pediatric dermatology**Clindamycin**

antibiotic selection for MRSA (CR), 281

comparative study of tolerability of two combination therapies for acne (CTR), 597, 961

comparison of novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin, 812

development and optimization of fixed combination of clindamycin and benzoyl peroxide aqueous gel for acne vulgaris, 634

efficacy and safety of two topical combination acne regimens, 624

evaluation of tolerability of two topical drug products for facial acne (CTR), 1054

FDA approval of Acanya™ gel for acne (PP), 194

fixed combination of clindamycin phosphate and low concentration benzoyl peroxide aqueous gel for acne, 736

and rifampicin for hidradenitis suppurativa (PP), 1050

safety and efficacy of clindamycin phosphate and tretinoin gel for rosacea (CTR), 421, 597

simultaneous use of fixed topical antibiotic/benzoyl peroxide combination and topical retinoid for acne (CR), 1126

tolerability of clindamycin/tretinoin gel versus tretinoin microsphere gel and adapalene gel for acne, 383

**Clinical Trial Review (CTR)**, 87, 195, 312, 421, 499, 597, 685, 780, 885, 961, 1054, 1152**Clinical trials**

acellular matrix skin graft for diabetic foot ulcers (PP), 595

acid peel and laser for melasma (CTR), 425, 686, 887

acne treatment in children aged 9 to 11 (CTR), 961

adrenal function and use of intralesional triamcinolone acetonide in alopecia areata (CTR), 685, 886

ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 1055

alopecia areata registry and immunogenetic mechanisms (CTR), 685

API 31510 in topical cream for in situ cutaneous SCC (CTR), 313, 688, 964

API31510 in topical cream for in situ cutaneous SCC (CTR), 1155

appearance of photodamaged skin improved by stabilized 0.1% retinol facial moisturizer, 932

apremilast in atopic or contact dermatitis (CTR), 1153

azelaic acid versus hydroquinone in melasma (CTR), 887

AZX100 following excision of keloid scars (CTR), 312, 782

bicillin LA versus placebo for psoriasis unresponsive to topical medications (CTR), 687

botulinum toxin A for upper facial rhytids, patient perception of treatment outcomes, 924

botulinum toxin for psoriasis (CTR), 686, 963

botulinum toxin for seborrheic dermatitis in parkinsonian patients (CTR), 197

calcitriol BID topical treatment of psoriasis in (CTR), 782

CERTICOEUR: secondary prevention of skin cancers in heart transplant patients (CTR), 88

clobetasol propionate 0.05% spray versus calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for psoriasis, 52

clobetasol propionate shampoo and antifungal shampoo in scalp seborrheic dermatitis (CTR), 501, 1057

coal tar plus narrow-band UVB light for psoriasis, 351

combining topical corticosteroid and LCD treatment for localized psoriasis (CTR), 501

comparative study of tolerability of two combination therapies for acne (CTR), 597, 961

comparison of novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin, 812

comparison of RevLite Electro-optic Q-switched Nd:YAG laser to fractionated laser system (CTR), 963

complete lymph node dissection versus observation in localized melanoma with sentinel node metastasis (CTR), 502, 965

concurrent Altanax® and topical low-potency corticosteroids versus low-potency corticosteroid monotherapy for atopic dermatitis (CTR), 780, 962

contact allergies in patients with chronic urticaria (CTR), 889

dapson gel and tazarotene cream versus tazarotene cream monotherapy for facial acne (CTR), 421, 499, 597

dapson gel and tretinoin gel versus tretinoin gel monotherapy for facial acne (CTR), 421

dasatinib for unresectable or metastatic SCC (CTR), 783

desloratadine with levocetirizine for chronic idiopathic urticaria (CTR), 90, 601

dose finding study of AEB071 assessing psoriasis area and severity index (CTR), 781

efalizumab for alopecia (CTR), 195

effectiveness and safety of 3 dosing regimens of CP-690,550 in psoriasis (CTR), 88

effects of microdermabrasion on skin remodeling (CTR), 87, 687

effects of pulsed-dyed laser on scar formation (CTR), 783

efficacy and safety of 4 dose regimens of

- oral albaconazole for distal subungual onychomycosis (CTR), 89
- efficacy and safety of apremilast (CC-10004) in psoriasis (CTR), 87, 500
- efficacy and safety of botulinum toxin A (NT 201) for glabellar frown lines (CTR), 87
- efficacy and safety of CIP-isotretinoin for recalcitrant nodular acne (CTR), 1054
- efficacy and safety of cyclosporine A microemulsion in maintenance patients with chronic plaque psoriasis (CTR), 781, 964
- efficacy and safety of GDC-0449 in advanced BCC (CTR), 502, 784, 964, 1156
- efficacy and safety of new U.S. botulinum toxin type A in retreatment of glabellar lines, 439
- efficacy and safety of omalizumab in bullous pemphigoid (CTR), 600
- efficacy and safety of two topical combination acne regimens, 624
- efficacy of bifonazole cream versus placebo after nail ablation with urea paste (CTR), 90
- efficacy of lipid-based barrier repair formulation in pediatric atopic dermatitis, 1106
- efficacy of montelukast in atopic dermatitis induced by food allergens (CTR), 598
- efficacy of single dose of three dose levels of AIN457 in psoriasis (CTR), 88, 500, 686
- enhanced safety aesthetic laser system (CTR), 688
- erlotinib + radiotherapy for cutaneous SCC (CTR), 783, 1155
- erlotinib for vulvar SCC (CTR), 313
- etanercept for psoriasis (PRISTINE) (CTR), 500
- etanercept in dermatomyositis (CTR), 196, 423
- evaluation of sentinel lymph nodes in head and neck SCC (CTR), 964
- evaluation of tolerability of two topical drug products for facial acne (CTR), 1054
- fixed combination of clindamycin phosphate and low concentration benzoyl peroxide aqueous gel for acne, 736
- 4-week study of pimecrolimus for seborrheic dermatitis (CTR), 197, 501
- FV-100 versus valacyclovir in herpes zoster (CTR), 785, 1056
- hand NB-UVB versus Excilite treatment in vitiligo after minigrafting on dorsal hands (CTR), 197
- hyaluronic acid needle-free injection for damaged and wrinkled skin (CTR), 312
- imatinib in patients with mucosal or acral/lentiginous melanoma (CTR), 502
- imiquimod for infantile hemangioma (PP), 595
- imiquimod in children with plaque morphea (CTR), 196, 423
- impact of treating *Staphylococcus aureus* infection and colonization on clinical severity of atopic dermatitis (CTR), 422
- infliximab for pemphigus vulgaris (CTR), 599
- infrared imaging of cutaneous melanoma (CTR), 1156
- injectable biologic and U0279 combination therapy for psoriasis (CTR), 686, 888, 963, 1057
- intralesional injections of botulinum toxin for alopecia areata of scalp (CTR), 886
- intralesional triamcinolone acetonide for alopecia areata (CTR), 196
- intratumoral injection of alpha-GAL glycosphingolipids (CTR), 1156
- Intron-A/Aldara combination therapy for BCC (CTR), 502
- IV/PO moxifloxacin for complicated skin infection (CTR), 313
- IVlg with or without cyclophosphamide in pemphigus (CTR), 599
- Jessner's solution versus trichloroacetic acid for melasma (CTR), 425, 686, 887
- Juvista in scar revision surgery of disfiguring scars (CTR), 782
- ketoconazole for seborrheic dermatitis (CTR), 197, 501
- LDE225 for skin BCC in Gorlin's syndrome (CTR), 1157
- lenalidomide for cutaneous lupus erythematosus (CTR), 196, 424, 1154
- light treatment and laser treatment for melasma (CTR), 425, 685, 887
- liposomal methylene blue hydrogel for selective PDT of acne vulgaris, 983
- long-term effects of imiquimod and diclofenac for AK (CTR), 1054
- long-term safety of MEDI-545 in systemic lupus erythematosus or myositis (CTR), 1153
- methotrexate for fingernail psoriasis (CTR), 312
- methyl aminolevulinate PDT in patients with skin type V or IV with acne vulgaris (CTR), 499, 597, 961
- methyl aminolevulinate PDT in subjects with field AKs, BCCs, or Bowen's disease (CTR), 195, 689, 965
- methylene blue mediated PDT for psoriasis, 42
- nasolabial fold filler study for people of color (CTR), 687, 889
- natural vitamin E tocotrienol for treatment of surgical scars (CTR), 783
- neoadjuvant imatinib in dermatofibrosarcoma protuberans (CTR), 1157
- novel oligopeptide for melasma, 732
- NT 201 versus botulinum toxin A for glabellar frown lines (CTR), 312
- omalizumab in adults with chronic urticaria who exhibit IgE against thyroperoxidase (CTR), 90
- omalizumab in patients with chronic idiopathic urticaria who remain symptomatic with antihistamine treatment (CTR), 601, 890
- oral contraceptive containing 3 mg drospirenone plus 20 g ethinylestradiol for acne, 837
- oral glutamine to suppress recurrent herpes labialis (CTR), 784, 1055
- PDT for actinic damage in patients with SCC of lip (CTR), 501, 688
- PDT in treating patients with skin cancer (CTR), 89
- PDT in treatment of acne (CTR), 499, 780
- PDT using ALA in treating patients with skin cancer (CTR), 88, 689, 965
- phase 2b trial of EPB-348 for herpes zoster (CTR), 1056
- phase II AK study in organ transplant patients (CTR), 1055
- phototherapy with topical retinoid versus phototherapy alone for AK (CTR), 195, 885, 1054
- plant-based dietary intervention for acne (CTR), 780
- pulsed dye laser and nonablative laser for abdominoplasty scars (CTR), 312
- purpura-free treatment of lentigines using a long-pulsed 595 nm pulsed dye laser with compression handpiece, s18 (November)
- Regenecare® wound gel for rash in patients receiving cetuximab or other epidermal growth factor receptor inhibitor therapy for cancer (CTR), 1054
- Remicade in psoriasis patients with inadequate response to etanercept (CTR), 500
- Restylane and Perlane in correction of perioral wrinkles (CTR), 1056
- retapamulin versus linezolid in SITL and impetigo due to MRSA (CTR), 503, 784
- rituximab for bullous pemphigoid (CTR), 599
- rituximab for dermatomyositis and polymyositis (CTR), 423
- rituximab in ocular cicatricial pemphigoid (CTR), 600
- safety, efficacy, and pharmacokinetics of PZ-601 for complicated skin infection (CTR), 90, 601
- safety and effectiveness of AK treatment following cryosurgery (CTR), 885
- safety and effectiveness of etanercept for lichen planus on oral mucosa or skin (CTR), 500
- safety and efficacy of abatacept in subjects with chronic urticaria after inadequate response to antihistamine therapy (CTR), 601
- safety and efficacy of alefacept in atopic dermatitis (CTR), 422
- safety and efficacy of Botox for acne (CTR), 195, 421
- safety and efficacy of clindamycin phosphate and tretinoin gel for rosacea (CTR), 421, 597
- safety and efficacy of daptomycin for complicated skin infections (CTR), 90
- safety and efficacy of drospirenone and ethinyl estradiol (YAZ) versus placebo in acne vulgaris (CTR), 499, 961
- safety and efficacy of etanercept in discoid lupus erythematosus (CTR), 424, 1155
- safety and efficacy of infliximab in palmoplantar psoriasis (CTR), 888
- safety and efficacy of RT001 for lateral canthal lines (CTR), 1056
- safety and pharmacokinetics of famciclovir in adolescents with recurrent herpes labialis (CTR), 600
- safety and tolerability of ILV-094 in psoriasis (CTR), 687
- safety of AMG 157 in atopic dermatitis (CTR), 422, 598, 781, 962, 1152
- safety of hyaluronic acid versus hyaluronic acid combined with lidocaine (CTR), 87
- safety of teplizumab in psoriasis (CTR), 964
- safety study of clinical and immune effects of Phosphodiesterase-4 inhibitor in cutaneous lupus erythematosus (CTR), 424, 1154
- Scholtz-Dumas bioassay comparison of fluocinonide 0.1% cream, clobetasol 0.05% cream, and halobetasol 0.05% cream for psoriasis, 751
- sequential PDT and imiquimod 5% cream for AK, 35
- spironolactone pills versus minoxidil lotion in female pattern hair loss (CTR), 196, 423, 685, 886, 1152
- study of acne treatment in children (CTR), 780
- study to evaluate switch from etanercept to infliximab in psoriasis (CTR), 782
- T cell agents for psoriasis, s6 (May, T Cell Agents)
- Taclonex ointment with hydrogel patch occlusion for psoriasis (CTR), 887, 1057
- tocotrienol for surgical scars (CTR), 313
- tolerability of clindamycin/tretinoin gel versus tretinoin microsphere gel and adapalene gel for acne, 383
- topical 2% green tea lotion for acne, 358
- topical ALA in nonmelanoma skin cancer (CTR), 88
- topical azelaic acid 15% gel combined with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy for, 639
- topical azelaic acid gel plus anti-inflammatory dose doxycycline or metronidazole gel in rosacea (CTR), 598
- topical calcipotriol for AK, 451
- topical cyclosporin for ocular rosacea (CTR), 422
- topical imiquimod cream combined with

- cryotherapy for AK (CTR), 885  
 topical myristyl nicotinate cream on skin of healthy volunteers (CTR), 89  
 topical perillyl alcohol for sun damaged skin and AK (CTR), 195, 885, 1055  
 topical sulindac combined with hydrogen peroxide for AK, 29  
 topical tazarotene for BCC and basal cell nevus syndrome on chest and back (CTR), 689  
 topical tazarotene for BCC and basal cell nevus syndrome on face (CTR), 1155  
 topical treatment for hand dermatitis (CTR), 197  
 transdermal bupivacaine patch for postherpetic neuralgia (CTR), 89  
 treatment of androgenetic alopecia in males (CTR), 1152  
 treatment of cutaneous lupus erythematosus with 595 nm flashlamp pulsed dye laser (CTR), 196, 424, 1154  
 treatment of keloid scars post-shave excision with imiquimod 5% cream, 455  
 treatment of patients with blepharitis and facial rosacea (CTR), 422  
 tretinoin microsphere gel pump versus tazarotene cream for facial acne, 650  
 TUMORAPA 1: efficacy of rapamycin in secondary prevention of skin cancers in kidney transplant recipients (CTR), 88  
 2940 nm fractional photothermolysis laser for acne scarring, 978  
 vitamin D levels in patients with chronic urticaria and angioedema (CTR), 889  
 vitamin D supplementation in childhood atopic dermatitis (CTR), 963  
 vitamin K oxide gel in resolution of postprocedural purpura, 1020  
 Xyzal for pruritus in atopic dermatitis (CTR), 598, 781, 962, 1152  
 ZD1839 for recurrent or metastatic SCC of skin (CTR), 89, 688  
 zinc for herpes simplex labialis (CTR), 313, 600  
**Clobetasol**  
 clobetasol propionate 0.05% spray versus calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for psoriasis, 52  
 clobetasol propionate shampoo and antifungal shampoo in scalp seborrheic dermatitis (CTR), 501, 1057  
 combining topical corticosteroid and LCD treatment for localized psoriasis (CTR), 501  
 ointments versus other vehicles for corticosteroid treatment of psoriasis, 570  
 Scholtz-Dumas bioassay comparison of fluocinonide 0.1% cream, clobetasol 0.05% cream, and halobetasol 0.05% cream for psoriasis, 751  
 skin concentrations following topical versus oral steroid treatment, 1076  
 topical, 1093  
**Cloccortolone**, topical, 1093  
**Clofazimine**, 846  
**Coal tar**  
 foam for psoriasis (PP), 310  
 plus narrow-band UVB light for psoriasis, 351  
**Coffee berry**, s5 (June)  
**Colchicine**, for chronic urticaria (NVR), 1043  
**Collagen**  
 advances in collagen fillers, s12 (April)  
 Canadian report on the safety and effectiveness of Evolence® Breeze™, 830  
 dissolving collagen fillers (CR), 1140  
 filler revolution: six-year perspective, 903  
 introduction to supplement on facial rejuvenation, s3 (April)  
 lip augmentation and contour correction with collagen dermal filler, s1 (March)  
 long-term evaluation of collagen and elastin after infrared irradiation, 708  
 science and art of dermal fillers for soft-tissue augmentation, 335  
**Colloidal oatmeal**, s5 (June)  
**Connective tissue disorders**  
 clofazimine for lupus erythematosus, 846  
 lenalidomide for cutaneous lupus erythematosus (CTR), 196, 424, 1154  
 long-term safety of MEDI-545 in systemic lupus erythematosus or myositis (CTR), 1153  
 mycophenolate mofetil in systemic sclerosis (CTR), 1153  
 safety and efficacy of etanercept in discoid lupus erythematosus (CTR), 424, 1155  
 safety study of clinical and immune effects of Phosphodiesterase-4 inhibitor in cutaneous lupus erythematosus (CTR), 424, 1154  
 treatment of cutaneous lupus erythematosus with 595 nm flashlamp pulsed dye laser (CTR), 196, 424, 1154  
**Contact dermatitis**  
 apremilast in atopic or contact dermatitis (CTR), 1153  
 contact allergens in children and adults (NVR), 79  
 cosmetic and hand sanitizer allergies (NVR), 308  
 metal allergies (NVR), 307  
 molecular and cellular characteristics of spongiotic dermatitis (CTR), 197  
 in patients with chronic urticaria (CTR), 889  
**Corticosteroids**  
 adrenal function and use of intralesional triamcinolone acetonide in alopecia areata (CTR), 685, 886  
 alclometasone dipropionate cream (PP), 883  
 clobetasol propionate 0.05% spray versus calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for psoriasis, 52  
 combining topical corticosteroid and LCD treatment for localized psoriasis (CTR), 501  
 concurrent Altanax® and topical low-potency corticosteroids versus low-potency corticosteroid monotherapy for atopic dermatitis (CTR), 780, 962  
 FDA approval for betamethasone dipropionate cream, 0.05% (augmented) (PP), 92  
 hydrocortisone/acyclovir cream approved by FDA (PP), 959  
 intralesional steroid injections for alopecia areata, 909  
 intralesional triamcinolone acetonide for alopecia areata (CTR), 196  
 intramuscular triamcinolone (CR), 580  
 linear hypopigmentation and cutaneous atrophy after intra-articular steroid injections for de Quervain's tendonitis (CR), 492  
 ointments versus other vehicles for corticosteroid treatment of psoriasis, 570  
 Scholtz-Dumas bioassay comparison of fluocinonide 0.1% cream, clobetasol 0.05% cream, and halobetasol 0.05% cream for psoriasis, 751  
 for seborrheic dermatitis, 125  
 skin concentrations following topical versus oral steroid treatment, 1076  
 therapies for cutaneous T-cell lymphoma (NVR), 1143  
 topical, 1093  
**Cosmetic allergies (NVR)**, 308  
**Cosmetic dermatology**  
 ablative fractionated CO2 laser resurfacing for neck, 723  
 advanced techniques for Sculptra, s17 (April)  
 advances in collagen fillers, s12 (April)  
 appearance of photodamaged skin improved by stabilized 0.1% retinol facial moisturizer, 932  
 applied anatomy of temporal region and forehead for injectable fillers, s24 (October)  
 Beer Hand Scale to grade dorsal hand aging, s9 (April)  
 Belotero® Balance PMA filing accepted (PP), 1051  
 botulinum toxin A for upper facial rhytids, patient perception of treatment outcomes, 924  
 calcium hydroxylapatite: safety, techniques, and pain reduction, s21 (October)  
 Canadian report on the safety and effectiveness of Evolence® Breeze™, 830  
 clinical impressions of fractional ablative resurfacing devices, 481  
 Coapt Systems launches Hydrelle™ (PP), 1051  
 combination of radiothermoplasty and fractionated laser technology (PP), 310  
 combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and calcium hydroxylapatite, s21 (April)  
 cosmeceuticals for aging skin (NVR), 674  
 disfiguring scarring after mesotherapy-associated *Mycobacterium cosmeticum* infection (CR), 391  
 efficacy and safety of new U.S. botulinum toxin type A in retreatment of glabellar lines, 439  
 eMatrix skin resurfacing system (PP), 193  
 enhanced safety aesthetic laser system (CTR), 688  
 FDA approves poly-L-lactic acid for nasolabial folds (PP), 959  
 filler revolution: six-year perspective, 903  
 fistula development on neck after nonablative radiofrequency (CR), 172  
 full-face treatments with 2790-nm erbium-YSGG laser system, 248  
 grading system for malar crease region and implications for treatment with soft-tissue augmentation products, s5 (April)  
 high-frequency radiowave system granted FDA clearance (PP), 959  
 histological comparison of 1064 nm Nd:YAG and 1320 nm Nd:YAG laser lipolysis, 377  
 introduction to supplement on facial rejuvenation, s3 (April)  
 Juvista in scar revision surgery of disfiguring scars (CTR), 782  
 laser treatment of dark skin, 821  
 lip augmentation and contour correction with collagen dermal filler, s1 (March)  
 Lipostabil® Endovena for aging neck, 937  
 Medicis begins shipping Dysport™ for glabellar lines (PP), 884  
 mobile delivery of infrared light (1100–1800 nm) for treatment of facial and neck skin laxity, 221  
 nanotechnology in cosmetics and sunscreens (NVR), 955  
 nasolabial fold filler study for people of color (CTR), 687  
 patient satisfaction and duration of effect with PLLA, s15 (October)  
 permanent laser hair removal with low fluence high repetition rate versus high fluence low repetition rate 810 nm diode laser, s14 (November)  
 purpura-free treatment of lentigines using a long-pulsed 595 nm pulsed dye laser with compression handpiece, s18 (November)  
 science and art of dermal fillers for soft-tissue augmentation, 335  
 skin resurfacing with novel microablative CO2 laser, 138

- SmartSkin™ fractional laser for photodamage and acne scars, s4 (November)
- stronger warning labels for fillers (PP), 194
- superficial chemical peels, 803
- topical growth factors, s4 (May, Growth Factors)
- twelve-month labeling approval for Evolence (PP), 960
- use of hydroquinone/tretinoin skin care system in patients undergoing intense pulsed light therapy for photorejuvenation, 862
- use of natural products in, s5 (June)
- for hyperpigmentation, s10 (June)
- introduction to supplement on, s4 (June)
- using poly-L-lactic acid to mimic volume in multiple tissue layers, s5 (October)
- validated rating scale for management of lip fullness and aging options, s24 (April)
- VASER® Lipo for body contouring and fat transfer (PP), 1050
- Cost effectiveness**, of Mohs micrographic surgery, 914
- CP-690,550**, effectiveness and safety of 3 dosing regimens in psoriasis (CTR), 88
- Cryotherapy**
- combined with imiquimod cream for AK (CTR), 885
- safety and effectiveness of AK treatment following (CTR), 885
- Curcumin**, s5 (June)
- Cutaneous aging**
- ALA PDT in acne, vitiligo and photoaging, 562
- Beer Hand Scale to grade dorsal hand aging, s9 (April)
- clinical impressions of fractional ablative resurfacing devices, 481
- combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and calcium hydroxylapatite, s21 (April)
- genomic-driven insights into changes in, s8 (July)
- genomics of (editorial), s3 (July)
- hyaluronic acid needle-free injection for damaged and wrinkled skin (CTR), 312
- Lipostabil® Endovena for aging neck, 937
- metabolic pathways for skin anti-aging, s4 (July)
- practical applications of genomics research for treatment of, s15 (July)
- safety and effectiveness of Belotero® in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963
- topical perillyl alcohol for sun damaged skin and AK (CTR), 195, 885, 1055
- treatment of aging hand with Radiesse® (CR), 1122
- Cutaneous T-cell lymphoma**
- photopheresis for (PP), 497
- therapies for (NVR), 1143
- Cyclophosphamide**, IVlg with or without cyclophosphamide in pemphigus (CTR), 599
- Cyclosporine**
- efficacy and safety of cyclosporine A microemulsion in maintenance patients with chronic plaque psoriasis (CTR), 781, 964
- topical, for ocular rosacea (CTR), 422
- D**
- Dapsone gel**
- and tazarotene cream versus tazarotene cream monotherapy for facial acne (CTR), 421, 499, 597
- and tretinoin gel versus tretinoin gel monotherapy for facial acne (CTR), 421
- Daptomycin**, safety and efficacy for complicated skin infections (CTR), 90
- Dasatinib**
- hair depigmentation during therapy with (CR), 395
- for unresectable or metastatic SCC (CTR), 783
- de Quervain's tendonitis**, linear hyperpigmentation and cutaneous atrophy after intra-articular steroid injections for (CR), 492
- Denileukin diftitox**, therapies for cutaneous T-cell lymphoma (NVR), 1143
- Dermatofibrosarcoma protuberans**, neoadjuvant imatinib in (CTR), 1158
- Dermatomyositis**
- etanercept in (CTR), 196, 423
- rituximab for polymyositis and (CTR), 423
- Dermatophyte infection**, tea tree oil for (NVR), 494
- Dermatosis cinecinta**, clofazimine for, 846
- Desloratadine**, with levocetirizine in chronic idiopathic urticaria (CTR), 90, 601
- Desonide**, topical, 1093
- Desoximetasone**, topical, 1093
- Devices and equipment**
- Bio-Synthesis™ light-activated rejuvenation device updated (PP), 1051
- clinical impressions of fractional ablative resurfacing devices, 481
- comparison of RevLite Electro-optic Q-switched Nd:YAG laser to fractionated laser system (CTR), 963
- eMatrix skin resurfacing system (PP), 193
- FDA guidelines for off-label drug and device use, 311
- FDA 510(k) clearance of new Fraxel re:store dual laser system (PP), 1152
- high-frequency radiowave system granted FDA clearance (PP), 959
- home-use intense pulsed light device for removal of (PP), 595
- MelaFind application accepted (PP), 960
- new fractional radiofrequency system for skin rejuvenation and repair, s9 (November)
- permanent hyperpigmentation after laser hair removal using dynamic cooling device (CR), 68
- purpura-free treatment of lentiginos using a long-pulsed 595 nm pulsed dye laser with compression handpiece, s18 (November)
- SmartSkin™ fractional laser for photodamage and acne scars, s4 (November)
- VASER® Lipo for body contouring and fat transfer (PP), 1050
- Viafirm™ Fat Transfer System (PP), 1051
- Diabetic foot ulcers**, acellular matrix skin graft for (PP), 595
- Diaper dermatitis**, Lansinoh Diaper Rash Ointment (PP), 883
- Diclofenac**, and imiquimod for AK, long-term effects (CTR), 1054
- Diet**, plant-based dietary intervention for acne (CTR), 780
- Diflorasone**, topical, 1093
- Doxycycline**
- anti-inflammatory dose, for rosacea, 664
- topical azelaic acid 15% gel combined with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy for, 639
- topical azelaic acid gel plus anti-inflammatory dose doxycycline or metronidazole gel in rosacea (CTR), 598
- Drospirenone and ethinyl estradiol (YAZ)**
- for acne, 837
- safety and efficacy versus placebo in acne vulgaris (CTR), 499, 961
- Drug reactions/toxicity**
- amlodipine-induced stasis dermatitis, 135
- autologous fat transfer for facial lipoatrophy, 486
- black tongue secondary to bismuth subsalicylate (CR), 1133
- carvedilol and hypersensitivity (PP), 960
- concurrent antiphospholipid syndrome and cutaneous sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C (CR), 870
- delayed onset nodules from liquid injectable silicone (CR), 952
- FDA advisory for Raptiva (PP), 497
- FDA alert on topical anesthetics (PP), 310
- FDA boxed warning for botulinum toxin products (PP), 595
- FDA finds cancer risk with TNF blockers (PP), 1050
- FDA warning for etravirine (PP), 1050
- hair depigmentation during dasatinib therapy (CR), 395
- infection in psoriasis and rheumatoid arthritis patients treated with antitumor necrosis factor agents and methotrexate (CR), 175
- isotretinoin-associated perioral abscess (CR), 1034
- linear hypopigmentation and cutaneous atrophy after intra-articular steroid injections for de Quervain's tendonitis (CR), 492
- Malassezia* folliculitis presented as acneiform eruption after cetuximab (CR), 274
- moxifloxacin-induced hypersensitivity syndrome (CR), 1031
- paclitaxel-related photodistributed erythema multiforme (CR), 61
- petechial and purpuric eruption induced by lidocaine/prilocaine cream (CR), 287
- Regenecare® wound gel for rash in patients receiving cetuximab or other epidermal growth factor receptor inhibitor therapy for cancer (CTR), 1054
- sorafenib-associated dyskeratotic plaque with milia (CR), 573
- tamoxifen-induced ultraviolet recall dermatitis (CR), 761
- Tarceva and bullous skin disorders, 682
- thalidomide-associated thromboembolic events in non-cancer setting (CR), 765
- topical pimecrolimus for cetuximab-associated eruption (PP), 1050
- topical retinoids and acne "flares," 799
- Treanda and toxic epidermal necrolysis (PP), 883
- Dutasteride**, for androgenetic alopecia (NVR), 185
- E**
- Economic issues**, cost effectiveness of Mohs micrographic surgery, 914
- Eczema**. See Atopic dermatitis
- Editorials**
- from the co-editors-in-chief, 9
- genomics of skin aging, s3 (July)
- Efalizumab**
- for alopecia (CTR), 195
- biologic survival, 329
- clinical update on T-cell modulators and investigational agents for psoriasis, 230
- FDA advisory for Raptiva (PP), 497
- hair regrowth after long-term efalizumab therapy for alopecia areata (CR), 758
- for inverse psoriasis (CR), 74
- management of psoriasis in the age of biologics, s2 (September), s5 (September)
- for psoriasis, s6 (May, T Cell Agents)
- Efudex**. See Fluorouracil cream
- Elastin**, long-term evaluation of collagen and elastin after infrared irradiation, 708
- Elidel**. See Pimecrolimus
- Enbrel**®. See Etanercept
- EPB-348, for herpes zoster (CTR), 1056
- EpiCeram**®
- efficacy in pediatric atopic dermatitis, 1106
- new skin barrier cream for atopic dermatitis (CR),

1037

**Erlotinib**

and radiotherapy for cutaneous SCC (CTR), 783, 1156

Tarceva and bullous skin disorders, 682

for vulvar SCC (CTR), 313

**Erythema multiforme**, photodistributed, paclitaxel-related (CR), 61**Etanercept**

anti-TNF agents for psoriasis, 546

for atopic dermatitis (CR), 873

biologic survival, 329

for chronic urticaria (NVR), 1043

clinical update on antitumor necrosis factor agents for psoriasis, 147

in dermatomyositis (CTR), 196, 423

follow-up of psoriatic arthritis mutilans patients treated with (CR), 406

management of psoriasis in the age of biologics, s2 (September), s5 (September)

and narrowband UVB for psoriasis (PP), 91

for pemphigus vulgaris (CR), 940

for psoriasis (PRISTINE) (CTR), 500

Remicade in psoriasis patients with inadequate response to (CTR), 500

safety and effectiveness for lichen planus on oral mucosa or skin (CTR), 500

safety and efficacy of etanercept in discoid lupus erythematosus (CTR), 424, 1156

study to evaluate switch from etanercept to infliximab in psoriasis (CTR), 782

and U0279 combination therapy for psoriasis (CTR), 686, 888, 963, 1057

**Extina**. See Ketoconazole**Eye shields and eye lubricants**, use during periorbital surgery, 855**Eyelashes**, bimatoprost for hypotrichosis of (PP), 92**Eyes**

botulinum toxin A for periorbital eccrine

hidrocystomas (CR), 71

rituximab in ocular cicatricial pemphigoid (CTR), 600

topical cyclosporin for ocular rosacea (CTR), 422

treatment of patients with blepharitis and facial rosacea (CTR), 422

**F****Face paint recall** (PP), 681**Facial lipoatrophy**

autologous fat transfer for, 486

3D imaging techniques in assessment of facial volume augmentation, 1113

**Facial rejuvenation**

advanced techniques for Sculptra, s17 (April)

advances in collagen fillers, s12 (April)

Bio-Synthesis™ light-activated rejuvenation device updated (PP), 1051

full-face treatments with 2790-nm erbium-YSGG laser system, 248

grading system for malar crease region and implications for treatment with soft-tissue augmentation products, s5 (April)

introduction to supplement on, s3 (April)

new fractional radiofrequency system for skin rejuvenation and repair, s9 (November)

skin rejuvenation and wrinkle reduction using a fractional radiofrequency system, 259

skin resurfacing with novel microablative CO2 laser, 138

superficial chemical peels, 803

topical growth factors, s4 (May, Growth Factors)

use of hydroquinone/tretinoin skin care system in patients undergoing intense pulsed light

therapy for, 862

**Facial seborrheic dermatitis**, 125**Facial telangiectasias**, vascular-specific laser wavelength for, 227**Famciclovir**, safety and pharmacokinetics in adolescents with recurrent herpes labialis (CTR), 600**Fat**

autologous fat transfer for facial lipoatrophy, 486

histological comparison of 1064 nm Nd:YAG and 1320 nm Nd:YAG laser lipolysis, 377

Lipostabil® Endovena for aging neck, 937

VASER® Lipo for body contouring and fat transfer (PP), 1050

Viafill™ Fat Transfer System (PP), 1051

**Feverfew**, s5 (June)**Finasteride**, for androgenetic alopecia (NVR), 185**Fistula**, development on neck after nonablative radiofrequency (CR), 172**Flea control in pets**, tea tree oil for (NVR), 494**Fluconazole**, and alpha-tocopherol for yellow nail syndrome (CR), 276**Fluocinolone**, topical, 1093**Fluocinonide**

Scholtz-Dumas bioassay comparison of fluocinonide 0.1% cream, clobetasol 0.05% cream, and halobetasol 0.05% cream for psoriasis, 751

topical, 1093

**Fluorouracil cream**, Efadex and rhytids (PP), 883**Fluphenazine hydrochloride**, for psoriasis (CTR), 888, 1057**Flurandrenolide**, topical, 1093**Fluticasone**, topical, 1093**Folliculitis**, *Malassezia*, presented as acneiform eruption after cetuximab (CR), 274**Foot lesions**

acellular matrix skin graft for diabetic foot ulcers (PP), 595

adalimumab for palmoplantar psoriasis (CR), 1137

intramuscular triamcinolone for (CR), 580

safety and efficacy of infliximab in palmoplantar psoriasis (CTR), 888

**Forehead**, applied anatomy of temporal region and forehead for injectable fillers, s24 (October)**Forodesine**, therapies for cutaneous T-cell lymphoma (NVR), 1143**Fractional thermolysis**

for hyperpigmentation (NVR), 879

SmartSkin™ fractional laser for photodamage and acne scars, s4 (November)

**Fractionated laser therapy**

ablative fractional laser resurfacing for treatment of third-degree burn (CR), 294

ablative fractionated erbium:YAG laser for ice pick alar scars due to neodymium:YAG laser burns (CR), 65

clinical impressions of fractional ablative resurfacing devices, 481

combination of radiothermoplasty and (PP), 310

eMatrix skin resurfacing system (PP), 193

fractionated CO2 laser resurfacing (CP), 82

non-ablative fractional resurfacing of scars, 998

for poikiloderma of Civatte, 527

skin resurfacing with novel microablative CO2 laser, 138

**Fungal infection**, efficacy and safety of 4 dose

regimens of oral albaconazole for distal

subungual onychomycosis (CTR), 89

**FV-100**, versus valacyclovir in herpes zoster (CTR),

785, 1056

**G****GDC-0449**, efficacy and safety in advanced BCC (CTR), 502, 784, 964, 1157**Gefitinib (ZD 1839)**, for recurrent or metastatic SCC of skin (CTR), 89, 688**Genetics**

of androgenetic alopecia (NVR), 185

genetic test for HPV (PP), 497

of psoriasis (NVR), 414

**Genistein**, s5 (June)**Genital warts**, beyond a decade of 5% imiquimod topical therapy, 467**Genomics**

to drive technology development for skin care, s12 (July)

insights into changes in aging skin, s8 (July)

metabolic pathways for skin anti-aging, s4 (July)

practical applications of research for treatment of aging skin, s15 (July)

of skin aging (editorial), s3 (July)

**Giant cell annular elastolytic granuloma**,

clofazimine for, 846

**Glabella lines**

efficacy and safety of botulinum toxin A (NT 201) for (CTR), 87

efficacy and safety of new U.S. botulinum toxin type A in retreatment of, 439

Medicis begins shipping Dysport™ for (PP), 884

NT 201 versus botulinum toxin A for (CTR), 312

Reloxin for (PP), 497

**Glutamine**, to suppress recurrent herpes labialis (CTR), 784, 1055**Glycolic acid**, superficial chemical peels, 803**Gorlin's syndrome**, LDE225 for skin BCC in (CTR), 1156**Graft versus host disease, cutaneous**, in treatment with psoralen plus UVA-bath photochemotherapy (CR), 1027**Granuloma annulare**

clofazimine for, 846

disseminated, adalimumab for (CR), 169

**Grape Seed extract**, s10 (June)**Green tea**, s5 (June)

lotion for acne, 358

**Growth factors, topical**, s4 (May, Growth Factors)**H****Hair**

hair depigmentation during dasatinib therapy (CR), 395

home-use intense pulsed light device for removal of (PP), 595

permanent hyperpigmentation after laser hair removal using dynamic cooling device (CR), 68

permanent laser hair removal with low fluence

high repetition rate versus high fluence

low repetition rate 810 nm diode laser, s14 (November)

**Hair loss**

adrenal function and use of intralesional triamcinolone acetonide in alopecia areata (CTR), 685, 886

alopecia areata registry and immunogenetic mechanisms (CTR), 685

diagnosis and treatment of androgenetic alopecia (NVR), 185

efalizumab for alopecia (CTR), 195

hair regrowth after long-term efalizumab therapy for alopecia areata (CR), 758

intralesional injections of botulinum toxin for alopecia areata of scalp (CTR), 886

intralesional steroid injections for alopecia areata, 909



- intralesional triamcinolone acetonide for alopecia areata (CTR), 196
- intramuscular triamcinolone for (CR), 580
- spironolactone pills versus minoxidil lotion in female pattern hair loss (CTR), 196, 423, 685, 886, 1153
- treatment of androgenetic alopecia in males (CTR), 1153
- Halcinonide**, topical, 1093
- Halobetasol**
- Scholtz-Dumas bioassay comparison of fluocinonide 0.1% cream, clobetasol 0.05% cream, and halobetasol 0.05% cream for psoriasis, 751
- topical, 1093
- Hand**
- adalimumab for palmoplantar psoriasis (CR), 1137
- alitretinoin for hand eczema (PP), 193
- Beer Hand Scale to grade dorsal hand aging, s9 (April)
- combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and calcium hydroxylapatite, s21 (April)
- forced cold air and topical anesthetic cream for analgesia during botulinum toxin injections for palmar hyperhidrosis (CR), 948
- hand NB-UVB versus Excilite treatment in vitiligo after minigrafting on dorsal hands (CTR), 197
- intramuscular triamcinolone for conditions of (CR), 580
- safety and efficacy of infliximab in palmoplantar psoriasis (CTR), 888
- topical treatment for hand dermatitis (CTR), 197
- treatment of aging hand with Radiesse® (CR), 1122
- treatment of verruca vulgaris with *Candida* antigen in patient with HIV (CR), 268
- Hand sanitizer allergies** (NVR), 308
- Head and neck SCC**, evaluation of sentinel lymph nodes in (CTR), 964
- Head lice**
- benzyl alcohol lotion for (PP), 682
- malathion for scabies and, 715
- Heart transplant recipients**, CERTICOEUR: secondary prevention of skin cancers in (CTR), 88
- Helicobacter pylori eradication**, for chronic urticaria (NVR), 1043
- Hemangioma**, infantile, imiquimod for (PP), 595
- Hepatitis C**, concurrent antiphospholipid syndrome and cutaneous sarcoidosis due to interferon alfa and ribavirin treatment for (CR), 870
- Herpes simplex labialis**
- hydrocortisone/acyclovir cream approved by FDA (PP), 959
- oral glutamine for suppression of (CTR), 784, 1055
- PDT for (PP), 595
- safety and pharmacokinetics of famciclovir in adolescents with (CTR), 600
- zinc for (CTR), 313, 600
- Herpes zoster**
- FV-100 versus valacyclovir in (CTR), 785, 1056
- phase 2b trial of EPB-348 for (CTR), 1056
- Hidradenitis suppurativa**
- adalimumab for (CR), 181
- clindamycin and rifampicin for (PP), 1050
- Hidrocystomas**, periorbital eccrine, botulinum toxin A for (CR), 71
- Histology**
- clinicopathologic profile of Becker's melanosis with atypical features, 745
- disseminated granuloma annulare (CR), 169
- fractionated CO2 laser resurfacing (CP), 82
- genomic-driven insights into changes in aging skin, s8 (July)
- histologic and clinical response to varying density settings with a fractionally scanned carbon dioxide laser, 17
- histological comparison of 1064 nm Nd:YAG and 1320 nm Nd:YAG laser lipolysis, 377
- isotretinoin-associated perioral abscess (CR), 1034
- long-term evaluation of collagen and elastin after infrared irradiation, 708
- metabolic pathways for skin anti-aging, s4 (July)
- methylene blue mediated PDT for psoriasis, 42
- nodular BCC appearing as morpheaform during Mohs micrographic surgery (CR), 163
- pityriasis rubra pilaris sensitive to narrow band UVB light therapy (CR), 270
- skin rejuvenation and wrinkle reduction using a fractional radiofrequency system, 259
- sorafenib-associated dyskeratotic plaque with milia (CR), 573
- tamoxifen-induced ultraviolet recall dermatitis (CR), 761
- History**, retrospective on 44 years in dermatologic surgery, 519
- Hormones**, in pathogenesis of acne vulgaris, 615
- Human immunodeficiency virus (HIV) disease**
- autologous fat transfer for facial lipoatrophy, 486
- FDA warning for etravirine (PP), 1050
- patient satisfaction and duration of effect with PLLA, s15 (October)
- treatment of verruca vulgaris with *Candida* antigen in patient with (CR), 268
- Human papillomavirus (HPV) infection**, genetic test for (PP), 497
- Hyaluronic acid**
- Beer Hand Scale to grade dorsal hand aging and response to treatments, s9 (April)
- Belotero® Balance PMA filing accepted (PP), 1051
- Coapt Systems launches Hydrelle™ (PP), 1051
- filler revolution: six-year perspective, 903
- needle-free injection for damaged and wrinkled skin (CTR), 312
- safety and effectiveness of Belotero® in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963
- safety of hyaluronic acid versus hyaluronic acid combined with lidocaine (CTR), 87
- science and art of dermal fillers for soft-tissue augmentation, 335
- for soft-tissue augmentation, 1086
- Hydrocortisone**
- hydrocortisone/acyclovir cream approved by FDA (PP), 959
- skin concentrations following topical versus oral steroid treatment, 1076
- topical, 1093
- Hydrogen peroxide**, with topical sulindac for AK, 29
- Hydroquinone**
- versus azelaic acid in melasma (CTR), 887
- use of hydroquinone/tretinoin skin care system in patients undergoing intense pulsed light therapy for photorejuvenation, 862
- Hyperhidrosis**
- axillary, 15% aluminum chloride in 2% salicylic acid gel base for, 477
- palmar, forced cold air and topical anesthetic cream for analgesia during botulinum toxin injections for (CR), 948
- Hyperpigmentation** (NVR), 879
- Hypersensitivity reactions**
- to carvedilol (PP), 960
- to moxifloxacin (CR), 1031
- Idiopathic nodular panniculitis**, clofazimine for, 846
- ILV-094**, safety and tolerability in psoriasis (CTR), 687
- Imaging**
- FDG-PET and CT in melanoma assessment (PP), 1151
- infrared imaging of cutaneous melanoma (CTR), 1157
- 3D imaging techniques in assessment of facial volume augmentation, 1113
- Imatinib**
- neoadjuvant, in dermatofibrosarcoma protuberans (CTR), 1158
- in patients with mucosal or acral/lentiginous melanoma (CTR), 502
- Imiquimod 5% cream**
- for AK (PP), 310
- beyond a decade of therapy with, 467
- in children with plaque morphea (CTR), 196, 423
- combined with cryotherapy for AK (CTR), 885
- and diclofenac for AK, long-term effects (CTR), 1054
- for infantile hemangioma (PP), 595
- Intron-A/Aldara combination therapy for BCC (CTR), 502
- and sequential PDT for AK, 35
- therapies for cutaneous T-cell lymphoma (NVR), 1143
- in treatment of keloid scars post-shave excision, 455
- Immune function**
- cutaneous chronic graft versus host disease in treatment with psoralen plus UVA-bath photochemotherapy (CR), 1027
- in pathogenesis of acne vulgaris, 615
- Immunomodulators**
- adalimumab for disseminated granuloma annulare (CR), 169
- adalimumab for hidradenitis suppurativa (CR), 181
- adalimumab for palmoplantar psoriasis (CR), 1137
- anti-TNF agents for psoriasis, 546
- beyond a decade of 5% imiquimod topical therapy, 467
- biologic survival, 329
- for chronic urticaria (NVR), 1043
- clinical update on antitumor necrosis factor agents for psoriasis, 147
- clinical update on T-cell modulators and investigational agents for psoriasis, 230
- efalizumab for inverse psoriasis (CR), 74
- efficacy and safety of cyclosporine A microemulsion in maintenance patients with chronic plaque psoriasis (CTR), 781, 964
- etanercept and U0279 combination therapy for psoriasis (CTR), 686, 888, 963, 1057
- etanercept for pemphigus vulgaris (CR), 940
- etanercept for psoriasis (PRISTINE) (CTR), 500
- etanercept in dermatomyositis (CTR), 196, 423
- FDA advisory for Raptiva (PP), 497
- hair regrowth after long-term efalizumab therapy for alopecia areata (CR), 758
- imiquimod in children with plaque morphea (CTR), 196, 423
- infection in psoriasis and rheumatoid arthritis patients treated with antitumor necrosis factor agents and methotrexate (CR), 175
- IVIg with or without cyclophosphamide in pemphigus (CTR), 599
- lenalidomide for cutaneous lupus erythematosus (CTR), 196, 424, 1155
- management of psoriasis in the age of biologics,

s2 (September), s5 (September)  
 narrowband UVB and etanercept for psoriasis (PP), 91  
 safety and effectiveness of etanercept for lichen planus on oral mucosa or skin (CTR), 500  
 safety and efficacy of etanercept in discoid lupus erythematosus (CTR), 424, 1156  
 safety and efficacy of infliximab in palmoplantar psoriasis (CTR), 888  
 for seborrheic dermatitis, 125  
 sequential PDT and imiquimod 5% cream for AK, 35  
 study to evaluate switch from etanercept to infliximab in psoriasis (CTR), 782  
 T cell agents for psoriasis, s6 (May, T Cell Agents)  
 thalidomide-associated thromboembolic events in non-cancer setting (CR), 765  
 topical imiquimod cream combined with cryotherapy for AK (CTR), 885  
 treatment of keloid scars post-shave excision with imiquimod 5% cream, 455  
**Impetigo**, retapamulin versus linezolid in SITL and impetigo due to MRSA (CTR), 503, 784  
**Incontinentia pigmenti**, topical tacrolimus for (CR), 944  
**Infection**  
 antibiotic selection for MRSA (CR), 281  
 antimicrobial activity of nitric oxide (NVR), 586  
 disfiguring scarring after mesotherapy-associated *Mycobacterium cosmeticum* infection (CR), 391  
 genetic test for HPV (PP), 497  
 impact of treating *Staphylococcus aureus* infection and colonization on clinical severity of atopic dermatitis (CTR), 422  
*Malassezia* folliculitis presented as acneiform eruption after cetuximab (CR), 274  
 nitric oxide-releasing nanoparticles and skin infection (PP), 681  
 PDT for herpes simplex labialis (PP), 595  
 in psoriasis and rheumatoid arthritis patients treated with antitumor necrosis factor agents and methotrexate (CR), 175  
 retapamulin versus linezolid in SITL and impetigo due to MRSA (CTR), 503, 784  
 safety, efficacy, and pharmacokinetics of PZ-601 for complicated skin infection (CTR), 90, 601  
 safety and efficacy of daptomycin for complicated skin infections (CTR), 90  
 safety and pharmacokinetics of famciclovir in adolescents with recurrent herpes labialis (CTR), 600  
 tea tree oil for (NVR), 494  
 Vibativ™ (telavancin) for skin infection (PP), 1152  
 wound packing after superficial skin abscess drainage (CTR), 503  
 zinc for herpes simplex labialis (CTR), 313, 600  
**Infliximab**  
 anti-TNF agents for psoriasis, 546  
 biologic survival, 329  
 clinical update on antitumor necrosis factor agents for psoriasis, 147  
 management of psoriasis in the age of biologics, s2 (September), s5 (September)  
 for pemphigus vulgaris (CTR), 599  
 Remicade in psoriasis patients with inadequate response to etanercept (CTR), 500  
 safety and efficacy in palmoplantar psoriasis (CTR), 888  
 study to evaluate switch from etanercept to infliximab in psoriasis (CTR), 782  
**Infrared irradiation**, long-term evaluation of collagen and elastin after, 708  
**Intense pulsed light**

home-use intense pulsed light device (PP), 595  
 use of hydroquinone/tretinoin skin care system in patients undergoing intense pulsed light therapy for photorejuvenation, 862

#### Interferon

concurrent antiphospholipid syndrome and cutaneous sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C (CR), 870

interferon-2a for verruca plantaris (PP), 193  
 Intron-A/Aldara combination therapy for BCC (CTR), 502

PegIntron for metastatic melanoma (PP), 1151  
 therapies for cutaneous T-cell lymphoma (NVR), 1143

**Interleukin-12/23 monoclonal antibodies**, clinical update on T-cell modulators and investigational agents for psoriasis, 230

**Intravenous immunoglobulin (IVIg)**, with or without cyclophosphamide in pemphigus (CTR), 599

**Intron-A**. See Interferon

**Iressa**. See Gefitinib

#### Isotretinoin

efficacy and safety of CIP-isotretinoin for recalcitrant nodular acne (CTR), 1054  
 Hoffmann-La Roche discontinues Accutane sales (PP), 883

perioral abscess associated with (CR), 1034

## J

#### Jessner's solution

superficial chemical peels, 803  
 versus trichloroacetic acid for melasma (CTR), 425, 686, 887

**Juvista**, in scar revision surgery of disfiguring scars (CTR), 782

## K

#### Keloid scars

AZX100 following excision of (CTR), 312, 782  
 post-shave excision, treatment with imiquimod 5% cream, 455

#### Ketoconazole

for androgenetic alopecia (NVR), 185  
 clobetasol propionate shampoo and antifungal shampoo in scalp seborrheic dermatitis (CTR), 501, 1057

for seborrheic dermatitis (CTR), 197, 501

**Kidney transplant recipients**, TUMORAPA 1: efficacy of rapamycin in secondary prevention of skin cancers in (CTR), 88

## L

**Labial arteries**, anatomic considerations for soft tissue augmentation of the face, 13

#### Laser technology

ablative fractional laser resurfacing for poikiloderma of Civatte, 527  
 ablative fractional laser resurfacing for treatment of third-degree burn (CR), 294  
 ablative fractionated CO2 laser resurfacing for neck, 723  
 ablative fractionated erbium:YAG laser for ice pick alar scars due to neodermis:YAG laser burns (CR), 65  
 acid peel and laser for melasma (CTR), 425, 686, 887

clinical impressions of fractional ablative resurfacing devices, 481

combination of radiothermoplasty and fractionated laser technology (PP), 310

comparison of RevLite Electro-optic Q-switched Nd:YAG laser to fractionated laser system (CTR), 963

effects of pulsed-dyed laser on scar formation (CTR), 783

eMatrix skin resurfacing system (PP), 193  
 enhanced safety aesthetic laser system (CTR), 688  
 FDA approval for Lumenis (PP), 311

FDA 510(k) clearance of new Fraxel re:store dual laser system (PP), 1152

fractionated CO2 laser resurfacing (CP), 82  
 full-face treatments with 2790-nm erbium-YSGG laser system, 248

histologic and clinical response to varying density settings with a fractionally scanned carbon dioxide laser, 17

histological comparison of 1064 nm Nd:YAG and 1320 nm Nd:YAG laser lipolysis, 377

laser treatment of dark skin, 821

light treatment and laser treatment for melasma (CTR), 425, 685, 887

new fractional radiofrequency system for skin rejuvenation and repair, s9 (November)

non-ablative fractional resurfacing of scars, 998

permanent hyperpigmentation after laser hair removal using dynamic cooling device (CR), 68

permanent laser hair removal with low fluence high repetition rate versus high fluence low repetition rate 810 nm diode laser, s14 (November)

pulsed dye laser and nonablative laser for abdominoplasty scars (CTR), 312

purpura-free treatment of lentiginos using a long-pulsed 595 nm pulsed dye laser with compression handpiece, s18 (November)

skin resurfacing with novel microablative CO2 laser, 138

SmartSkin™ fractional laser for photodamage and acne scars, s4 (November)

treatment of cutaneous lupus erythematosus with 595 nm flashlamp pulsed dye laser (CTR), 196, 424, 1155

2940 nm fractional photothermolysis laser for acne scarring, 978

use of low-fluence 1064 nm Nd:YAG laser in female with contraindications to systemic anti-acne therapy (CR), 1025

vascular-specific laser wavelength for facial telangiectasias, 227

Zcalm™ post-laser revitalizing cream available (PP), 1052

**LCD therapy**, combined with topical corticosteroid treatment for localized psoriasis (CTR), 501

**LDE225**, for skin BCC in Gorlin's syndrome (CTR), 1156

**Lenalidomide**, for cutaneous lupus erythematosus (CTR), 196, 424, 1155

**Lentiginos**, purpura-free treatment using a long-pulsed 595 nm pulsed dye laser with compression handpiece, s18 (November)

**Letter from the Guest Editor**, 214, 607

**Letters to the Editor**, 215

**Leukotriene inhibitors**, for chronic urticaria (NVR), 1043

**Levocetirizine**  
 for chronic idiopathic urticaria, 243  
 with desloratadine in chronic idiopathic urticaria (CTR), 90, 601

Xyzal for pruritus in atopic dermatitis (CTR), 598, 781, 962, 1153

**Lice**  
 benzyl alcohol lotion for head lice (PP), 682  
 malathion for head lice and scabies, 715

**Lichen planus**, intramuscular triamcinolone for

- (CR), 580
- Licorice extract**, s5 (June), s10 (June)
- Lidocaine**  
forced cold air and topical anesthetic cream for analgesia during botulinum toxin injections for palmar hyperhidrosis (CR), 948  
petechial and purpuric eruption induced by lidocaine/prilocaine cream (CR), 287  
safety of hyaluronic acid versus hyaluronic acid combined with lidocaine (CTR), 87
- Linezolid**  
antibiotic selection for MRSA (CR), 281  
versus retapamulin in SITL and impetigo due to MRSA (CTR), 503, 784
- Linoleic acid**, s10 (June)
- Lip**  
augmentation and contour correction with collagen dermal filler, s1 (March)  
PDT for actinic damage in patients with SCC of (CTR), 501, 688  
validated rating scale for management of lip fullness and aging options, s24 (April)
- Lipoatrophy, facial**  
autologous fat transfer for, 486  
3D imaging techniques in assessment of facial volume augmentation, 1113  
®-Lipohydroxy acid, superficial chemical peels, 803
- Lipolysis**, histological comparison of 1064 nm Nd:YAG and 1320 nm Nd:YAG laser lipolysis, 377
- Lipostabil® Endovena**, for aging neck, 937
- Lobomycosis**, clofazimine for, 846
- Lumixyl™**, for melasma, 732
- Lupus erythematosus**  
clofazimine for, 846  
cutaneous  
lenalidomide for (CTR), 196, 424, 1155  
safety study of clinical and immune effects of Phosphodiesterase-4 inhibitor in (CTR), 424, 1155  
treatment with 595 nm flashlamp pulsed dye laser (CTR), 196, 424, 1155  
long-term safety of MEDI-545 in systemic lupus erythematosus or myositis (CTR), 1154  
safety and efficacy of etanercept in discoid lupus erythematosus (CTR), 424, 1156
- Lymph nodes**  
complete lymph node dissection versus observation in localized melanoma with sentinel node metastasis (CTR), 502, 965  
evaluation of sentinel lymph nodes in head and neck SCC (CTR), 964
- M**
- Malacoplakia**, clofazimine for, 846
- Malar crease region**, grading system and implications for treatment with soft-tissue augmentation products, s5 (April)
- Malassezia folliculitis**, presented as acneiform eruption after cetuximab (CR), 274
- Malathion**, for head lice and scabies, 715
- MEDI-545**, long-term safety in systemic lupus erythematosus or myositis (CTR), 1154
- <-Melanocyte-stimulating hormone analogues (NVR), 772
- Melanoma**  
complete lymph node dissection versus observation in localized melanoma with sentinel node metastasis (CTR), 502, 965  
FDG-PET and CT in assessment of (PP), 1151  
imatinib in patients with mucosal or acral/lentiginous melanoma (CTR), 502  
infrared imaging of (CTR), 1157
- intratumoral injection of alpha-GAL glycosphingolipids (CTR), 1157
- MelaFind application accepted (PP), 960
- metastatic, PegIntron for (PP), 1151
- Melasma**  
acid peel and laser for (CTR), 425, 686, 887  
azelaic acid versus hydroquinone in (CTR), 887  
Jessner's solution versus trichloroacetic acid for (CTR), 425, 686, 887  
light treatment and laser treatment for (CTR), 425, 685, 887  
novel oligopeptide for, 732  
superficial chemical peels for, 803  
treatments for (NVR), 879
- Memorial, A. Bernard Ackerman MD**, 11
- Mesotherapy**, disfiguring scarring after *Mycobacterium cosmeticum* infection associated with (CR), 391
- Metal allergies** (NVR), 307
- Methotrexate**  
for fingernail psoriasis (CTR), 312  
infection in psoriasis and rheumatoid arthritis patients treated with antitumor necrosis factor agents and (CR), 175  
therapies for cutaneous T-cell lymphoma (NVR), 1143
- Methyl aminolevulinatE PDT**  
in patients with skin type V or IV with acne vulgaris (CTR), 499, 597, 961  
in subjects with field AK, BCCs, or Bowen's disease (CTR), 195, 689, 965  
for superficial BCC, 992
- Methylene blue**  
liposomal, for selective PDT of acne vulgaris, 983  
for PDT in psoriasis, 42
- Metronidazole**, topical azelaic acid gel plus anti-inflammatory dose doxycycline or metronidazole gel in rosacea (CTR), 598
- Microcyn gel**, FDA clearance for Microcyn (PP), 681
- Microdermabrasion**, effects on skin remodeling (CTR), 87, 687
- Minocycline**, simultaneous use of fixed topical antibiotic/benzoyl peroxide combination and topical retinoid for acne (CR), 1127
- Minoxidil**  
for androgenetic alopecia (NVR), 185  
spironolactone pills versus minoxidil lotion in female pattern hair loss (CTR), 196, 423, 685, 886, 1153
- Mohs micrographic surgery**  
cost effectiveness, 914  
development of, 519  
linear closure for nasal defects after, 23  
nodular BCC appearing as morpheaform during (CR), 163  
use of eye shields and eye lubricants by oculoplastic and Mohs surgeons, 855
- Moisturizers**, Albolene versus Mimyx for eczema (PP), 1151
- Mometasone**, topical, 1093
- Montelukast**, efficacy in atopic dermatitis induced by food allergens (CTR), 598
- Moxifloxacin**  
hypersensitivity syndrome induced by (CR), 1031  
IV/PO, for complicated skin infection (CTR), 313
- Mycobacterium cosmeticum infection**, mesotherapy-associated, disfiguring scarring after (CR), 391
- Mycophenolate mofetil**  
for chronic urticaria (NVR), 1043  
in systemic sclerosis (CTR), 1154
- Myositis**, long-term safety of MEDI-545 in systemic lupus erythematosus or (CTR), 1154
- Myristyl nicotinate cream**, on skin of healthy volunteers (CTR), 89
- N**
- Nail disorders**  
efficacy and safety of 4-dose regimens of oral albaconazole for distal subungual onychomycosis (CTR), 89  
efficacy of bifonazole cream versus placebo after nail ablation with urea paste (CTR), 90  
fluconazole and alpha-tocopherol for yellow nail syndrome (CR), 276  
methotrexate for fingernail psoriasis (CTR), 312
- Nanotechnology**, in cosmetics and sunscreens (NVR), 955
- Nasolabial folds**  
FDA approves poly-L-lactic acid for (PP), 959  
filler for people of color (CTR), 687  
filler study for people of color (CTR), 889  
safety and effectiveness of Belotero® in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963  
safety of hyaluronic acid versus hyaluronic acid combined with lidocaine (CTR), 87
- Natural products in cosmetic dermatology**, s5 (June)  
for hyperpigmentation, s10 (June)  
introduction to supplement on, s4 (June)
- Neck**  
ablative fractionated CO2 laser resurfacing for, 723  
evaluation of sentinel lymph nodes in head and neck SCC (CTR), 964  
fistula development on neck after nonablative radiofrequency (CR), 172  
Lipostabil® Endovena for aging neck, 937  
mobile delivery of infrared light (1100–1800 nm) for treatment of facial and neck skin laxity, 221
- Necrobiosis lipoidica**, clofazimine for, 846
- Nelarabine**, therapies for cutaneous T-cell lymphoma (NVR), 1143
- Neoplasia**  
ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 1055  
API 31510 in topical cream for in situ cutaneous SCC (CTR), 313, 688, 964  
API 31510 in topical cream for in situ cutaneous SCC (CTR), 1156  
CERTICOEUR: secondary prevention of skin cancers in heart transplant patients (CTR), 88  
complete lymph node dissection versus observation in localized melanoma with sentinel node metastasis (CTR), 502, 965  
cost effectiveness of Mohs micrographic surgery, 914  
dasatinib for unresectable or metastatic SCC (CTR), 783  
efficacy and safety of GDC-0449 in advanced BCC (CTR), 502, 784, 964, 1157  
erlotinib for vulvar SCC (CTR), 313  
erlotinib plus radiotherapy for cutaneous SCC (CTR), 783, 1156  
evaluation of sentinel lymph nodes in head and neck SCC (CTR), 964  
FDA finds cancer risk with TNF blockers (PP), 1050  
FDG-PET and CT in melanoma assessment (PP), 1151  
imatinib in patients with mucosal or acral/lentiginous melanoma (CTR), 502  
infrared imaging of cutaneous melanoma (CTR), 1157  
intratumoral injection of alpha-GAL glycosphingolipids (CTR), 1157

- Intron-A/Aldara combination therapy for BCC (CTR), 502
- LDE225 for skin BCC in Gorlin's syndrome (CTR), 1156
- linear closure for nasal defects after Mohs micrographic surgery, 23
- MelaFind application accepted (PP), 960
- methyl aminolevulinate PDT in subjects with field AK, BCCs, or Bowen's disease (CTR), 195, 689, 965
- neoadjuvant imatinib in dermatofibrosarcoma protuberans (CTR), 1158
- nodular BCC appearing as morpheaform during Mohs micrographic surgery (CR), 163
- PDT for actinic damage in patients with SCC of lip (CTR), 501, 688
- PDT in treating patients with skin cancer (CTR), 89
- PDT using ALA in treating patients with skin cancer (CTR), 88, 689, 965
- PDT using methyl aminolevulinate for superficial BCC, 992
- PegIntron for metastatic melanoma (PP), 1151
- photopheresis for cutaneous T-cell lymphoma (PP), 497
- Regenecare® wound gel for rash in patients receiving cetuximab or other epidermal growth factor receptor inhibitor therapy for cancer (CTR), 1054
- therapies for cutaneous T-cell lymphoma (NVR), 1143
- topical ALA in nonmelanoma skin cancer (CTR), 88
- topical tazarotene for BCC and basal cell nevus syndrome on chest and back (CTR), 689
- topical tazarotene for BCC and basal cell nevus syndrome on face (CTR), 1156
- TUMORAPA 1: efficacy of rapamycin in secondary prevention of skin cancers in kidney transplant recipients (CTR), 88
- ZD1839 for recurrent or metastatic SCC of skin (CTR), 89, 688
- News, Views & Reviews (NVR)**, 79, 185, 307, 414, 494, 586, 674, 772, 879, 955, 1043, 1143
- Niacinamide**, s10 (June)
- Nitric oxide**
- nitric oxide-releasing nanoparticles and skin infection (PP), 681
- therapeutic potential in dermatology (NVR), 586
- Nonsteroidal anti-inflammatory drugs**
- long-term effects of imiquimod and diclofenac for AK (CTR), 1054
- topical agent for pruritus in atopic dermatitis, 537
- topical sulindac combined with hydrogen peroxide for AK, 29
- Nose**
- ablative fractionated erbium:YAG laser for ice pick alar scars due to neodymium:YAG laser burns (CR), 65
- linear closure for nasal defects after Mohs micrographic surgery, 23
- NT 201**, versus botulinum toxin A for glabellar frown lines (CTR), 312
- O**
- 2-Octylethylcyanoacrylate tissue adhesives**
- FDA marketing clearance for SurgiSeal (PP), 193
- versus rapid absorbing gut suture in epidermal closure of linear repairs, 115
- Off-label drug and device use**, FDA guidelines for (PP), 311
- Oleic acid**, s10 (June)
- Olive oil**, s5 (June)
- Omalizumab**
- in adults with chronic urticaria who exhibit IgE against thyroperoxidase (CTR), 90
- for chronic urticaria (NVR), 1043
- efficacy and safety in bullous pemphigoid (CTR), 600
- in patients with chronic idiopathic urticaria who remain symptomatic with antihistamine treatment (CTR), 601, 890
- Onychomycosis**, distal subungual, efficacy and safety of 4 dose regimens of oral albaconazole for (CTR), 89
- Oral contraceptives (OCs)**
- combined OC containing 3 mg drospirenone plus 20 mg ethinylestradiol for acne, 837
- safety and efficacy of drospirenone and ethinyl estradiol (YAZ) versus placebo in acne vulgaris (CTR), 499, 961
- Oral pathology**
- isotretinoin-associated perioral abscess (CR), 1034
- painful parotid hypertrophy with bulimia (CR), 577
- safety and effectiveness of etanercept for lichen planus on oral mucosa or skin (CTR), 500
- P**
- Paclitaxel**, photodistributed erythema multiforme related to (CR), 61
- Pain management**
- calcium hydroxylapatite: safety, techniques, and pain reduction, s21 (October)
- FDA alert on topical anesthetics (PP), 310
- forced cold air and topical anesthetic cream for analgesia during botulinum toxin injections for palmar hyperhidrosis (CR), 948
- petechial and purpuric eruption induced by lidocaine/prilocaine cream (CR), 287
- transdermal bupivacaine patch for postherpetic neuralgia (CTR), 89
- Paper mulberry**, s5 (June)
- Parkinson's disease**, botulinum toxin for seborrheic dermatitis in patients with (CTR), 197
- Parotid duct**, anatomic considerations for soft tissue augmentation of the face, 13
- Parotid hypertrophy**, with bulimia (CR), 577
- Patient satisfaction**
- and acne quality of life after treatment with tretinoin pump, 1080
- botulinum toxin A for upper facial rhytids, patient perception of treatment outcomes, 924
- and duration of effect with PLLA, s15 (October)
- Pediatric dermatology**
- acne treatment in children aged 9–11 (CTR), 961
- benzyl alcohol lotion for head lice (PP), 682
- calcitriol BID topical treatment for adolescents with psoriasis (CTR), 782
- contact dermatitis in children (NVR), 79
- efficacy of lipid-based barrier repair formulation in atopic dermatitis, 1106
- face paint recall (PP), 681
- FDA finds cancer risk with TNF blockers (PP), 1050
- imiquimod for infantile hemangioma (PP), 595
- imiquimod in children with plaque morphea (CTR), 196, 423
- malathion for head lice and scabies, 715
- safety and pharmacokinetics of famciclovir in adolescents with recurrent herpes labialis (CTR), 600
- study of acne treatment in children (CTR), 780
- topical tacrolimus for incontinentia pigmenti (CR), 944
- vitamin D supplementation in childhood atopic dermatitis (CTR), 963
- Pemphigoid**
- bullous
- efficacy and safety of omalizumab in (CTR), 600
- rituximab for (CTR), 599
- ocular cicatricial, rituximab in (CTR), 600
- Pemphigus**
- etanercept for (CR), 940
- infliximab for (CTR), 599
- IVIg with or without cyclophosphamide in (CTR), 599
- Perillyl alcohol**, topical, for sun damaged skin and AK (CTR), 195, 885
- Perioral abscess**, isotretinoin-associated (CR), 1034
- Periorbital surgery**, use of eye shields and eye lubricants during, 855
- Pharmacokinetics**
- of LDE225 for skin BCC in Gorlin's syndrome (CTR), 1156
- safety, efficacy and pharmacokinetics of PZ-601 for complicated skin infection (CTR), 90, 601
- Phosphodiesterase-4 inhibitor**, safety study of clinical and immune effects in cutaneous lupus erythematosus (CTR), 424, 1155
- Photoaging**. *See also* Cutaneous aging
- ALA PDT in acne, vitiligo and, 562
- appearance of photodamaged skin improved by stabilized 0.1% retinol facial moisturizer, 932
- Beer Hand Scale to grade dorsal hand aging, s9 (April)
- clinical impressions of fractional ablative resurfacing devices, 481
- combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and calcium hydroxylapatite, s21 (April)
- cosmeceuticals for aging skin (NVR), 674
- hyaluronic acid needle-free injection for damaged and wrinkled skin (CTR), 312
- long-term evaluation of collagen and elastin after infrared irradiation, 708
- Restylane and Perlane in correction of perioral wrinkles (CTR), 1056
- safety and effectiveness of Belotero® in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963
- SmartSkin™ fractional laser for photodamage and acne scars, s4 (November)
- superficial chemical peels for, 803
- topical perillyl alcohol for sun damaged skin and AK (CTR), 195, 885, 1055
- Photodynamic therapy (PDT)**
- for actinic damage in patients with SCC of lip (CTR), 501, 688
- ALA PDT in acne, photoaging and vitiligo, 562
- ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 1055
- blue light PDT for acne vulgaris in African-American patient (CR), 669
- for herpes simplex labialis (PP), 595
- liposomal methylene blue hydrogel for selective PDT of acne vulgaris, 983
- methyl aminolevulinate PDT in patients with skin type V or IV with acne vulgaris (CTR), 499, 597, 961
- methyl aminolevulinate PDT in subjects with field AKs, BCCs, or Bowen's disease (CTR), 195, 689, 965
- methylene blue mediated PDT for psoriasis, 42
- PDT using methyl aminolevulinate for superficial BCC, 992
- phototherapy with topical retinoid versus phototherapy alone for AK (CTR), 195, 885, 1054
- review of PDT for acne vulgaris, 1010
- sequential PDT and imiquimod 5% cream for AK, 35

- in treating patients with skin cancer (CTR), 89  
 in treatment of acne (CTR), 499, 780  
 using ALA in treating patients with skin cancer (CTR), 88, 689, 965
- Photopheresis**, for cutaneous T-cell lymphoma (PP), 497
- Photopneumatic therapy**  
 for acne, 239
- Aesthera announces innovations (PP), 498
- Photosensitivity**, paclitaxel-related  
 photodistributed erythema multiforme (CR), 61
- Phototherapy**  
 for androgenetic alopecia (NVR), 185  
 for chronic urticaria (NVR), 1043  
 coal tar plus narrow-band UVB light for psoriasis, 351  
 hand NB-UVB versus Excilite treatment in vitiligo after minigrafting on dorsal hands (CTR), 197  
 light treatment and laser treatment for melasma (CTR), 425, 685, 887  
 mobile delivery of infrared light (1100–1800 nm) for treatment of facial and neck skin laxity, 221  
 narrowband UVB and etanercept for psoriasis (PP), 91  
 pityriasis rubra pilaris sensitive to narrow band UVB light therapy (CTR), 270  
 therapies for cutaneous T-cell lymphoma (NVR), 1143  
 with topical retinoid versus phototherapy alone for AK (CTR), 195, 885, 1054
- Pigmentation**  
 acid peel and laser for melasma (CTR), 425, 686, 887  
 azelaic acid versus hydroquinone in melasma (CTR), 887  
 black tongue secondary to bismuth subsalicylate (CR), 1133  
 clinicopathologic profile of Becker's melanosis with atypical features, 745  
 hair depigmentation during dasatinib therapy (CR), 395  
 hyperpigmentation (NVR), 879  
 Jessner's solution versus trichloroacetic acid for melasma (CTR), 425, 686, 887  
 light treatment and laser treatment for melasma (CTR), 425, 685, 887  
 linear hypopigmentation and cutaneous atrophy after intra-articular steroid injections for de Quervain's tendonitis (CR), 492  
 natural products for hyperpigmentation, s10 (June)  
 nitric oxide in regulation of (NVR), 586  
 novel oligopeptide for melasma, 732  
 permanent hyperpigmentation after laser hair removal using dynamic cooling device (CR), 68  
 topical prostaglandin E2 for vitiligo (PP), 91
- Pimecrolimus**  
 for cetuximab-associated eruption (PP), 1050  
 four-week study of treatment for seborrheic dermatitis (CTR), 197, 501
- Pipeline Previews (PP)**  
 acellular matrix skin graft for diabetic foot ulcers, 595  
 Aesthera announces innovations, 498  
 Albolene versus Mimyx for eczema, 1151  
 alitretinoin for hand eczema, 193  
 approval of Epiduo® acne gel, 92, 194  
 Bausch & Lomb and Besivance™, 884  
 Belotero® Balance PMA filing accepted, 1051  
 BenzEfoam Emollient Foam for body acne, 1151  
 benzoyl peroxide wash for acne, 310  
 benzyl alcohol lotion for head lice, 682  
 bimatoprost for hypotrichosis of eyelashes, 92  
 Bio-Synthesis™ light-activated rejuvenation device updated, 1051  
 carvedilol and hypersensitivity, 960  
 clindamycin and rifampicin for hidradenitis suppurativa, 1050  
 coal tar foam for psoriasis, 310  
 Coapt Systems launches Hydrelle™, 1051  
 combination of radiothermoplasty and fractionated laser technology, 310  
 Daavlin and UVA1 phototherapy cabinet, 310  
 Efudex and rhytids, 883  
 eMatrix skin resurfacing system, 193  
 face paint recall, 681  
 FDA advisory for Raptiva, 497  
 FDA alert on topical anesthetics, 310  
 FDA approval for betamethasone dipropionate cream, 0.05% (augmented), 92  
 FDA approval for Lumenis, 311  
 FDA approval for Vectical, 497  
 FDA approves Acanya™ gel for acne, 194  
 FDA approves poly-L-lactic acid for nasolabial folds, 959  
 FDA approves Stelara for psoriasis, 1151  
 FDA approves Sulfacetamide sodium topical, 681  
 FDA boxed warning for botulinum toxin products, 595  
 FDA clearance for Microcyn, 681  
 FDA finds cancer risk with TNF blockers, 1050  
 FDA guidelines for off-label drug and device use, 311  
 FDA marketing clearance for SurgiSeal, 193  
 FDA rejects ceftobiprole, 193  
 FDA warning for etravirine, 1050  
 FDG-PET and CT in melanoma assessment, 1151  
 genetic test for HPV, 497  
 Glenmark Generics and alclometasone dipropionate cream, 883  
 high-frequency radiowave system granted FDA clearance, 959  
 Hoffmann-La Roche discontinues Accutane sales, 883  
 home-use intense pulsed light device, 595  
 hydrocortisone/acyclovir cream approved by FDA, 959  
 imiquimod and actinic keratoses, 310  
 imiquimod for infantile hemangioma, 595  
 interferon-2a for verruca plantaris, 193  
 label changes for sunscreen (PP), 681  
 Lansinoh Diaper Rash Ointment, 883  
 Medcis begins shipping Dysport™ for glabellar lines, 884  
 MelaFind application accepted, 960  
 narrowband UVB and etanercept for psoriasis, 91  
 nitric oxide-releasing nanoparticles and skin infection (PP), 681  
 PDT for herpes simplex labialis, 595  
 PegIntron for metastatic melanoma, 1151  
 Perrigo and Sulfacetamide Sodium Topical Suspension, 498  
 photopheresis for cutaneous T-cell lymphoma, 497  
 recall of topical acne cream, 92  
 Reloxin for rhytids, 497  
 safety warnings for botulinum toxin, 959  
 Spear Dermatology Products introduces Refissa™ tretinoin cream, 884  
 stronger warning labels for fillers, 194  
 Tarceva and bullous skin disorders, 682  
 three times weekly tacrolimus ointment for atopic dermatitis, 91  
 topical pimecrolimus for cetuximab-associated eruption, 1050  
 topical prostaglandin E2 for vitiligo, 91  
 Treanda and toxic epidermal necrolysis, 883  
 twelve-month labeling approval for Evolence, 960  
 VASER® Lipo for body contouring and fat transfer, 1050
- Viafill™ Fat Transfer System, 1051  
 Vibativ™ (telavancin) for skin infections, 1152  
 Zcalm™ post-laser revitalizing cream available, 1052
- Pityriasis rubra pilaris**  
 sensitive to narrow band UVB light therapy (CR), 270  
 tinea versicolor mimicking (CR), 490
- Poikiloderma of Civatte**, ablative fractional laser resurfacing for, 527
- Poly-L-lactic acid (PLLA)**  
 advanced techniques for Sculptra, s17 (April)  
 approved acid for nasolabial folds (PP), 959  
 Beer Hand Scale to grade dorsal hand aging and response to treatments, s9 (April)  
 filler revolution: six-year perspective, 903  
 to mimic volume in multiple tissue layers, s5 (October)  
 patient satisfaction and duration of effect with, s15 (October)  
 science and art of dermal fillers for soft-tissue augmentation, 335
- Polymyositis**, rituximab for dermatomyositis and (CTR), 423
- Polypodium leucotomos**, s10 (June)
- Pomegranate**, s5 (June)
- Postherpetic neuralgia**, transdermal bupivacaine patch for (CTR), 89
- Prednicarbate**, topical, 1093
- Pregnancy**, use of low-fluence 1064 nm Nd:YAG laser in female with contraindications to systemic anti-acne therapy (CR), 1025
- Prevention**  
 ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 1055  
 CERTICOEUR: secondary prevention of skin cancers in heart transplant patients (CTR), 88  
 TUMORAPA 1: efficacy of rapamycin in secondary prevention of skin cancers in kidney transplant recipients (CTR), 88
- Prilocaine**, petechial and purpuric eruption induced by lidocaine/prilocaine cream (CR), 287
- PRK 124 lotion**, for rosacea, 459
- Proanthocyanidins**, s10 (June)
- Propionibacterium acnes**, 615. *See also* Acne vulgaris
- Prostaglandin E2**, topical, for vitiligo (PP), 91
- Pruritus**  
 in atopic dermatitis, topical nonsteroidal agent for, 537  
 in atopic dermatitis, Xyzal for (CTR), 598, 781, 962, 1153  
 intramuscular triamcinolone for (CR), 580
- Psoriasis**  
 adalimumab for palmoplantar psoriasis (CR), 1137  
 anti-TNF agents for, 546  
 bicillin LA versus placebo for psoriasis unresponsive to topical medications (CTR), 687  
 biologic survival, 329  
 botulinum toxin for (CTR), 686, 963  
 calcitriol 3 µg/g ointment for, s17 (August)  
 efficacy and safety of, s9 (August)  
 introduction to supplement on, s3 (August)  
 optimizing therapy with, s23 (August)  
 calcitriol BID topical treatment for adolescents with (CTR), 782  
 clinical update on antitumor necrosis factor agents for, 147  
 clinical update on T-cell modulators and investigational agents for, 230

clobetasol propionate 0.05% spray versus calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for, 52  
 coal tar foam for (PP), 310  
 coal tar plus narrow-band UVB light for, 351  
 combining topical corticosteroid and LCD treatment for localized psoriasis (CTR), 501  
 dose finding study of AEB071 assessing psoriasis area and severity index (CTR), 781  
 effectiveness and safety of 3 dosing regimens of CP-690,550 in (CTR), 88  
 efficacy and safety of apremilast (CC-10004) in (CTR), 87, 500  
 efficacy and safety of cyclosporine A microemulsion in maintenance patients with (CTR), 781, 964  
 efficacy of single dose of three dose levels of AIN457 in (CTR), 88, 500, 686  
 etanercept for (PRISTINE) (CTR), 500  
 FDA approval for Vectical (PP), 497  
 FDA approves Stelara for (PP), 1151  
 fluphenazine hydrochloride for (CTR), 888, 1057  
 generalized pustular, clofazimine for, 846  
 genetics of (NVR), 414  
 infection in patients treated with antitumor necrosis factor agents and methotrexate (CR), 175  
 injectable biologic and U0279 combination therapy for (CTR), 686, 888, 963, 1057  
 intramuscular triamcinolone for (CR), 580  
 inverse, efalizumab for (CR), 74  
 management in age of biologics, s2 (September), s5 (September)  
 methotrexate for fingernail psoriasis (CTR), 312  
 methylene blue mediated PDT for, 42  
 molecular and cellular characteristics of spongiotic dermatitis (CTR), 197  
 narrowband UVB and etanercept for (PP), 91  
 ointments versus other vehicles for corticosteroid treatment of, 570  
 Remicade in psoriasis patients with inadequate response to etanercept (CTR), 500  
 role of topical vitamin D modulators for, s4 (August)  
 safety and efficacy of infliximab in palmoplantar psoriasis (CTR), 888  
 safety and tolerability of ILV-094 in (CTR), 687  
 safety of teplizumab in (CTR), 964  
 Scholtz-Dumas bioassay comparison of fluocinonide 0.1% cream, clobetasol 0.05% cream, and halobetasol 0.05% cream for, 751  
 skin concentrations following topical versus oral steroid treatment, 1076  
 study to evaluate switch from etanercept to infliximab (CTR), 782  
 T cell agents for, s6 (May), T Cell agents)  
 Taclonex ointment with hydrogel patch occlusion for (CTR), 887, 1057

**Purpura**  
 postprocedural, vitamin K oxide gel in resolution of, 1020  
 purpura-free treatment of lentigines using a long-pulsed 595 nm pulsed dye laser with compression handpiece, s18 (November)

**Pyoderma gangrenosum**, clofazimine for, 846

**PZ-601**, for complicated skin infection, safety, efficacy, and pharmacokinetics of (CTR), 90, 601

## Q

**Quinolones**, antibiotic selection for MRSA (CR), 281  
**Quinupristin-dalfopristin**, antibiotic selection for MRSA (CR), 281

## R

**Race/ethnicity**  
 blue light PDT for acne vulgaris in an African-American patient (CR), 669  
 laser treatment of dark skin, 821  
 nasolabial fold filler study for people of color (CTR), 687, 889  
 safety and effectiveness of Belotero® in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963

**Radiation therapy**  
 and erlotinib for cutaneous SCC (CTR), 783, 1156  
 therapies for cutaneous T-cell lymphoma (NVR), 1143

**Radiesse®**, for treatment of aging hand (CR), 1122

**Radiofrequency**  
 combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and calcium hydroxylapatite, s21 (April)  
 new fractional radiofrequency system for skin rejuvenation and repair, s9 (November)  
 nonablative, fistula development on neck after (CR), 172  
 skin rejuvenation and wrinkle reduction using a fractional radiofrequency system, 259

**Radiothermoplasty**, combination of fractionated laser technology and (PP), 310

**Rapamycin**, TUMORAPA 1: efficacy in secondary prevention of skin cancers in kidney transplant recipients (CTR), 88

**Raptiva**. See Efalizumab

**Reloxin**. See Botulinum toxin A

**Remicade**. See Infliximab

**Restylane®**. See Hyaluronic acid

**Retapamulin**, versus linezolid in SITT and impetigo due to MRSA (CTR), 503, 784

**Retinoids**  
 acne quality of life and patient satisfaction after treatment with tretinoin pump, 1080  
 alitretinoin for hand eczema (PP), 193  
 appearance of photodamaged skin improved by stabilized 0.1% retinol facial moisturizer, 932  
 dapsone gel and tazarotene cream versus tazarotene cream monotherapy for facial acne (CTR), 421, 499, 597  
 dapsone gel and tretinoin gel versus tretinoin gel monotherapy for facial acne (CTR), 421  
 efficacy and safety of CIP-isotretinoin for recalcitrant nodular acne (CTR), 1054  
 efficacy and safety of two topical combination acne regimens, 624  
 Hoffmann-La Roche discontinues Accutane sales (PP), 883  
 isotretinoin-associated perioral abscess (CR), 1034  
 phototherapy with topical retinoid versus phototherapy alone for AK (CTR), 195, 885, 1054  
 safety and efficacy of clindamycin phosphate and tretinoin gel for rosacea (CTR), 421, 597  
 simultaneous use of fixed topical antibiotic/benzoyl peroxide combination and topical retinoid for acne (CR), 1127  
 Spear Dermatology Products introduces Refissa™ tretinoin cream (PP), 884  
 therapies for cutaneous T-cell lymphoma (NVR), 1143  
 tolerability of clindamycin/tretinoin gel versus tretinoin microsphere gel and adapalene gel for acne, 383  
 topical retinoids and acne "flares," 799  
 topical tazarotene for BCC and basal cell nevus syndrome on chest and back (CTR), 689  
 topical tazarotene for BCC and basal cell nevus syndrome on face (CTR), 1156

tretinoin microsphere gel pump versus tazarotene cream for facial acne, 650  
 use of hydroquinone/tretinoin skin care system in patients undergoing intense pulsed light therapy for photorejuvenation, 862

**REVLIMID®**. See Lenalidomide

**Rheumatoid arthritis**, infection in patients treated with antitumor necrosis factor agents and methotrexate (CR), 175

**Ribavirin**, concurrent antiphospholipid syndrome and cutaneous sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C (CR), 870

**Rifampicin**, and clindamycin for hidradenitis suppurativa (PP), 1050

**Rifampin**, antibiotic selection for MRSA (CR), 281

**Rituximab**  
 for bullous pemphigoid (CTR), 599  
 for chronic urticaria (NVR), 1043  
 for dermatomyositis and polymyositis (CTR), 423  
 in ocular cicatricial pemphigoid (CTR), 600

**Rosacea**  
 anti-inflammatory dose doxycycline for, 664  
 common issues that concern patients with, 120  
 ocular, topical cyclosporin for (CTR), 422  
 papulopustular, treatment with sodium sulfacetamide 10%/sulfur 5% emollient foam (CR), 299  
 safety and efficacy of clindamycin phosphate and tretinoin gel for (CTR), 421, 597  
 topical azelaic acid gel plus anti-inflammatory dose doxycycline or metronidazole gel in (CTR), 598  
 topical PRK 124 lotion for, 459  
 treatment of patients with blepharitis and facial rosacea (CTR), 422

**RT001**, safety and efficacy for lateral canthal lines (CTR), 1056

## S

**Safety issues**  
 AZX100 following excision of keloid scars (CTR), 312, 782  
 calcium hydroxylapatite: safety, techniques, and pain reduction, s21 (October)  
 Canadian report on the safety and effectiveness of Evolence® Breeze™, 830  
 carvedilol and hypersensitivity (PP), 960  
 desloratadine with levocetirizine for chronic idiopathic urticaria (CTR), 90, 601  
 effectiveness and safety of 3 dosing regimens of CP-690,550 in psoriasis (CTR), 88  
 efficacy and safety of apremilast (CC-10004) in psoriasis (CTR), 87, 500  
 efficacy and safety of botulinum toxin A (NT 201) for glabellar frown lines (CTR), 87  
 efficacy and safety of CIP-isotretinoin for recalcitrant nodular acne (CTR), 1054  
 efficacy and safety of cyclosporine A microemulsion in maintenance patients with chronic plaque psoriasis (CTR), 781, 964  
 efficacy and safety of GDC-0449 in advanced BCC (CTR), 502, 784, 964, 1157  
 efficacy and safety of new U.S. botulinum toxin type A in retreatment of glabellar lines, 439  
 efficacy and safety of omalizumab in bullous pemphigoid (CTR), 600  
 efficacy and safety of topical calcitriol ointment for psoriasis, s9 (August)  
 efficacy and safety of two topical combination acne regimens, 624  
 enhanced safety aesthetic laser system (CTR), 688  
 face paint recall (PP), 681  
 FDA boxed warning for botulinum toxin products

- (PP), 595  
 FDA warning for etravirine (PP), 1050  
 fixed combination of clindamycin phosphate and low concentration benzoyl peroxide aqueous gel for acne, 736  
 LDE225 for skin BCC in Gorlin's syndrome (CTR), 1156  
 long-term safety of MEDI-545 in systemic lupus erythematosus or myositis (CTR), 1154  
 malathion for head lice and scabies, 715  
 mobile delivery of infrared light (1100–1800 nm) for treatment of facial and neck skin laxity, 221  
 non-ablative fractional resurfacing of scars, 998  
 safety, efficacy, and pharmacokinetics of PZ-601 for complicated skin infection (CTR), 90, 601  
 safety and effectiveness of AK treatment following cryosurgery (CTR), 885  
 safety and effectiveness of Belotero® in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963  
 safety and effectiveness of etanercept for lichen planus on oral mucosa or skin (CTR), 500  
 safety and efficacy of abatacept in subjects with chronic urticaria after inadequate response to antihistamine therapy (CTR), 601  
 safety and efficacy of alefacept in atopic dermatitis (CTR), 422  
 safety and efficacy of Botox for acne (CTR), 195  
 safety and efficacy of clindamycin phosphate and tretinoin gel for rosacea (CTR), 421, 597  
 safety and efficacy of daptomycin for complicated skin infections (CTR), 90  
 safety and efficacy of drospirenone and ethinyl estradiol (YAZ) versus placebo in acne vulgaris (CTR), 499, 961  
 safety and efficacy of etanercept in discoid lupus erythematosus (CTR), 424, 1156  
 safety and efficacy of infliximab in palmoplantar psoriasis (CTR), 888  
 safety and efficacy of RT001 for lateral canthal lines (CTR), 1056  
 safety and pharmacokinetics of famciclovir in adolescents with recurrent herpes labialis (CTR), 600  
 safety and tolerability of ILV-094 in psoriasis (CTR), 687  
 safety of AMG 157 in atopic dermatitis (CTR), 422, 598, 781, 962, 1153  
 safety of API 31510 in topical cream for in situ cutaneous SCC (CTR), 313, 688, 964  
 safety of hyaluronic acid versus hyaluronic acid combined with lidocaine (CTR), 87  
 safety of teplizumab in psoriasis (CTR), 964  
 safety study of clinical and immune effects of Phosphodiesterase-4 inhibitor in cutaneous lupus erythematosus (CTR), 424, 1155  
 stronger warning labels for fillers (PP), 194  
 2940 nm fractional photothermolysis laser for acne scarring, 978  
 use of eye shields and eye lubricants during periorbital surgery, 855  
 use of low-fluence 1064 nm Nd:YAG laser in female with contraindications to systemic anti-acne therapy (CR), 1025  
 warnings for botulinum toxin (PP), 959  
**Salicylic acid**, superficial chemical peels, 803  
**Sarcoidosis**, concurrent antiphospholipid syndrome and cutaneous sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C (CR), 870  
**Scabies**, malathion for head lice and, 715  
**Scalp lesions**  
 benzyl alcohol lotion for head lice (PP), 682  
 clobetasol propionate shampoo and antifungal shampoo in scalp seborrheic dermatitis (CTR), 501, 1057  
 malathion for head lice and scabies, 715  
**Scarring**  
 ablative fractionated erbium:YAG laser for ice pick alar scars due to neodymium:YAG laser burns (CR), 65  
 AZX100 following excision of keloid scars (CTR), 312, 782  
 disfiguring scarring after mesotherapy-associated *Mycobacterium cosmeticum* infection (CR), 391  
 effects of pulsed-dyed laser on scar formation (CTR), 783  
 Juvista in scar revision surgery of disfiguring scars (CTR), 782  
 natural vitamin E tocotrienol for treatment of surgical scars (CTR), 783  
 non-ablative fractional resurfacing of scars, 998  
 pulsed dye laser and nonablative laser for abdominoplasty scars (CTR), 312  
 SmartSkin™ fractional laser for photodamage and acne scars, s4 (November)  
 tocotrienol for surgical scars (CTR), 313  
 treatment of keloid scars post-shave excision with imiquimod 5% cream, 455  
 2940 nm fractional photothermolysis laser for acne scarring, 978  
**Sculptra**. See Poly-L-lactic acid  
**Seborrheic dermatitis**  
 botulinum toxin for parkinsonian patients with (CTR), 197  
 clobetasol propionate shampoo and antifungal shampoo in scalp dermatitis (CTR), 501, 1057  
 facial, 125  
 4-week study of pimecrolimus for (CTR), 197, 501  
 ketoconazole for (CTR), 197, 501  
 tea tree oil for (NVR), 494  
**Sifalimumab**, long-term safety of MEDI-545 in systemic lupus erythematosus or myositis (CTR), 1154  
**Silicone**  
 liquid injectable, delayed onset nodules from (CR), 952  
 science and art of dermal fillers for soft-tissue augmentation, 335  
**Skin cancer**  
 ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 1055  
 API 31510 in topical cream for in situ cutaneous SCC (CTR), 313, 688, 964  
 API 31510 in topical cream for in situ cutaneous SCC (CTR), 1156  
 CERTICOEUR: secondary prevention of skin cancers in heart transplant patients (CTR), 88  
 complete lymph node dissection versus observation in localized melanoma with sentinel node metastasis (CTR), 502, 965  
 cost effectiveness of Mohs micrographic surgery, 914  
 dasatinib for unresectable or metastatic SCC (CTR), 783  
 efficacy and safety of GDC-0449 in advanced BCC (CTR), 502, 784, 964, 1157  
 erlotinib for vulvar SCC (CTR), 313  
 erlotinib plus radiotherapy for cutaneous SCC (CTR), 783, 1156  
 evaluation of sentinel lymph nodes in head and neck SCC (CTR), 964  
 FDG-PET and CT in melanoma assessment (PP), 1151  
 imatinib in patients with mucosal or acral/lentiginous melanoma (CTR), 502  
 infrared imaging of cutaneous melanoma (CTR), 1157  
 intratumoral injection of alpha-GAL glycosphingolipids (CTR), 1157  
 Intron-A/Aldara combination therapy for BCC (CTR), 502  
 LDE225 for skin BCC in Gorlin's syndrome (CTR), 1156  
 linear closure for nasal defects after Mohs micrographic surgery, 23  
 MelaFind application accepted (PP), 960  
 methyl aminolevulinate PDT in subjects with field AK, BCCs, or Bowen's disease (CTR), 195, 689, 965  
 neoadjuvant imatinib in dermatofibrosarcoma protuberans (CTR), 1158  
 nodular BCC appearing as morpheaform during Mohs micrographic surgery (CR), 163  
 PDT for actinic damage in patients with SCC of lip (CTR), 501, 688  
 PDT in treating patients with (CTR), 89  
 PDT using ALA in treating patients with (CTR), 88, 689, 965  
 PDT using methyl aminolevulinate for superficial BCC, 992  
 PegIntron for metastatic melanoma (PP), 1151  
 therapeutic potential of nitric oxide (NVR), 586  
 therapies for cutaneous T-cell lymphoma (NVR), 1143  
 topical ALA in nonmelanoma skin cancer (CTR), 88  
 topical tazarotene for BCC and basal cell nevus syndrome on chest and back (CTR), 689  
 topical tazarotene for BCC and basal cell nevus syndrome on face (CTR), 1156  
 TUMORAPA 1: efficacy of rapamycin in secondary prevention of skin cancers in kidney transplant recipients (CTR), 88  
 ZD1839 for recurrent or metastatic SCC of skin (CTR), 89, 688  
**Skin Cancer Foundation**, 519  
**Skin graft**, acellular matrix skin graft for diabetic foot ulcers (PP), 595  
**Skin remodeling**  
 effects of microdermabrasion on (CTR), 87, 687  
 topical growth factors in, s4 (May, Growth Factors)  
**Skin resurfacing**  
 ablative fractional laser resurfacing for poikiloderma of Civatte, 527  
 ablative fractional laser resurfacing for treatment of third-degree burn (CR), 294  
 ablative fractionated CO2 laser resurfacing for neck, 723  
 clinical impressions of fractional ablative resurfacing devices, 481  
 combination of radiothermoplasty and fractionated laser technology for (PP), 310  
 combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and calcium hydroxylapatite, s21 (April)  
 eMatrix skin resurfacing system (PP), 193  
 fractionated CO2 laser resurfacing (CP), 82  
 full-face treatments with 2790-nm erbium-YSGG laser system, 248  
 with novel microablative CO2 laser, 138  
**Skin tightening**  
 combination of radiothermoplasty and fractionated laser technology for (PP), 310  
 fistula development on neck after nonablative radiofrequency (CR), 172  
 mobile delivery of infrared light (1100–1800 nm) for treatment of facial and neck skin laxity, 221  
**Sodium sulfacetamide 10%/sulfur 5% emollient**

- foam**, for papulopustular rosacea (CR), 299
- Soft-tissue augmentation**
- advanced techniques for Sculptra, s17 (April)
- advances in collagen fillers, s12 (April)
- applied anatomy of temporal region and forehead for injectable fillers, s24 (October)
- autologous fat transfer for facial lipoatrophy, 486
- Beer Hand Scale to grade dorsal hand aging and response to treatments, s9 (April)
- Belotero® Balance PMA filing accepted (PP), 1051
- calcium hydroxylapatite: safety, techniques, and pain reduction, s21 (October)
- Canadian report on the safety and effectiveness of Evolence® Breeze™, 830
- Coapt Systems launches Hydrelle™ (PP), 1051
- combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and calcium hydroxylapatite, s21 (April)
- delayed onset nodules from liquid injectable silicone (CR), 952
- dissolving collagen fillers (CR), 1141
- of face, anatomic considerations for, 13
- filler revolution: six-year perspective, 903
- grading system for malar crease region and implications for treatment with products for, s5 (April)
- hyaluronics for, 1086
- introduction to supplement on facial rejuvenation, s3 (April)
- lip augmentation and contour correction with collagen dermal filler, s1 (March)
- nasolabial fold filler study for people of color (CTR), 889
- patient satisfaction and duration of effect with PLLA, s15 (October)
- safety of hyaluronic acid versus hyaluronic acid combined with lidocaine (CTR), 87
- science and art of dermal fillers for, 335
- 3D imaging techniques in assessment of facial volume augmentation, 1113
- treatment of aging hand with Radiesse® (CR), 1122
- twelve-month labeling approval for Evolence (PP), 960
- using poly-L-lactic acid to mimic volume in multiple tissue layers, s5 (October)
- validated rating scale for management of lip fullness and aging options, s24 (April)
- Sorafenib**, dyskeratotic plaque with milia associated with (CR), 573
- Soy**, s5 (June), s10 (June)
- Spiro lactone pills**, versus minoxidil lotion in female pattern hair loss (CTR), 196, 423, 685, 886, 1153
- Spongiotic dermatitis**, molecular and cellular characteristics (CTR), 197
- Squamous cell carcinoma (SCC)**
- API 31510 in topical cream for in situ cutaneous SCC (CTR), 313, 688, 964
- API 31510 in topical cream for in situ cutaneous SCC (CTR), 1156
- dasatinib for unresectable or metastatic SCC (CTR), 783
- erlotinib for vulvar SCC (CTR), 313
- erlotinib plus radiotherapy for cutaneous SCC (CTR), 783, 1156
- evaluation of sentinel lymph nodes in head and neck SCC (CTR), 964
- PDT for actinic damage in patients with SCC of lip (CTR), 501, 688
- ZD1839 for recurrent or metastatic SCC (CTR), 89, 688
- Staphylococcus aureus infection**
- impact of treating *Staphylococcus aureus* infection and colonization on clinical severity of atopic dermatitis (CTR), 422
- methicillin-resistant (MRSA)
- antibiotic selection for (CR), 281
- retapamulin versus linezolid in SITL and impetigo due to (CTR), 503, 784
- tea tree oil for (NVR), 494
- Stelara**. See Ustekinumab
- Stem cell therapy**, for androgenetic alopecia (NVR), 185
- Subcutaneous lipogranulomatosis**, clofazimine for, 846
- Sulfacetamide Sodium Topical Suspension (PP)**, 498, 681
- Sulfasalazine**, for chronic urticaria (NVR), 1043
- Sulfones**, for chronic urticaria (NVR), 1043
- Sulindac**, topical, with hydrogen peroxide for AK, 29
- Sunscreens**
- FDA proposes major changes to sunscreen regulations (WU), 891
- label changes for (PP), 681
- nanotechnology in cosmetics and (NVR), 955
- Supratrochlear artery**, anatomic considerations for soft tissue augmentation of the face, 13
- Sutures**, rapid absorbing gut suture versus 2-octylethylcyanoacrylate tissue adhesives in epidermal closure of linear repairs, 115
- Sweet's syndrome**, clofazimine for, 846
- Systemic sclerosis**, mycophenolate mofetil in (CTR), 1154
- T**
- T cell agents**, for psoriasis, s6 (May, T Cell Agents)
- Taclonex ointment**, with hydrogel patch occlusion for psoriasis (CTR), 887, 1057
- Tacrolimus ointment**
- for incontinencia pigmenti (CR), 944
- three times weekly, for atopic dermatitis (PP), 91
- Tamoxifen**, ultraviolet recall dermatitis induced by (CR), 761
- Tarceva**. See Erlotinib
- Tazarotene, topical**
- for BCC and basal cell nevus syndrome on chest and back (CTR), 689
- for BCC and basal cell nevus syndrome on face (CTR), 1156
- dapsone gel and tazarotene cream versus tazarotene cream monotherapy for facial acne (CTR), 421, 499, 597
- versus tretinoin microsphere gel pump for facial acne, 650
- Tea tree oil** (NVR), 494
- Telangiectasias, facial**, vascular-specific laser wavelength for, 227
- Telavancin**, for skin infection (PP), 1152
- Telemedicine**, 371
- Tendonitis**, linear hypopigmentation and cutaneous atrophy after intra-articular steroid injections for de Quervain's tendonitis (CR), 492
- Teplizumab**, safety in psoriasis (CTR), 964
- Tetracycline**, antibiotic selection for MRSA (CR), 281
- Tetrahydropranylidenine**, topical PRK 124 lotion for rosacea, 459
- Thalidomide**, thromboembolic events in non-cancer setting associated with (CR), 765
- Thermal injury**, ablative fractional laser resurfacing for treatment of third-degree burn (CR), 294
- Thromboembolic events**, thalidomide-associated, in non-cancer setting with (CR), 765
- Tinea versicolor**
- mimicking pityriasis rubra pilaris (CR), 490
- tea tree oil for (NVR), 494
- Tissue adhesives**
- FDA marketing clearance for SurgiSeal (PP), 193
- rapid absorbing gut suture versus 2-octylethylcyanoacrylate tissue adhesives in epidermal closure of linear repairs, 115
- Tissue fillers**
- advanced techniques for Sculptra, s17 (April)
- advances in collagen fillers, s12 (April)
- anatomic considerations for soft tissue augmentation of the face, 13
- applied anatomy of temporal region and forehead for injectable fillers, s24 (October)
- autologous fat transfer for facial lipoatrophy, 486
- Beer Hand Scale to grade dorsal hand aging and response to treatments, s9 (April)
- Belotero® Balance PMA filing accepted (PP), 1051
- calcium hydroxylapatite: safety, techniques, and pain reduction, s21 (October)
- Canadian report on the safety and effectiveness of Evolence® Breeze™, 830
- Coapt Systems launches Hydrelle™ (PP), 1051
- combination therapy of aging hand using non-ablative fractional resurfacing, radiofrequency and calcium hydroxylapatite, s21 (April)
- delayed onset nodules from liquid injectable silicone (CR), 952
- dissolving collagen fillers (CR), 1141
- FDA approves poly-L-lactic acid for nasolabial folds (PP), 959
- filler revolution: six-year perspective, 903
- grading system for malar crease region and implications for treatment with soft-tissue augmentation products, s5 (April)
- hyaluronics for soft-tissue augmentation, 1086
- introduction to supplement on facial rejuvenation, s3 (April)
- lip augmentation and contour correction with collagen dermal filler, s1 (March)
- nasolabial fold filler study for people of color (CTR), 687, 889
- patient satisfaction and duration of effect with PLLA, s15 (October)
- Restylane and Perlane in correction of perioral wrinkles (CTR), 1056
- safety and effectiveness of Belotero® in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963
- safety of hyaluronic acid versus hyaluronic acid combined with lidocaine (CTR), 87
- science and art of dermal fillers for soft-tissue augmentation, 335
- stronger warning labels for (PP), 194
- treatment of aging hand with Radiesse® (CR), 1122
- twelve-month labeling approval for Evolence (PP), 960
- using poly-L-lactic acid to mimic volume in multiple tissue layers, s5 (October)
- validated rating scale for management of lip fullness and aging options, s24 (April)
- Tocotrienol**, for surgical scars (CTR), 313
- Toll-like receptors**, in acne vulgaris, 615
- Topical anesthetics**
- FDA alert on (PP), 310
- petechial and purpuric eruption induced by lidocaine/prilocaine cream (CR), 287
- safety of hyaluronic acid versus hyaluronic acid combined with lidocaine (CTR), 87
- Toxic epidermal necrolysis**, Treanda and (PP), 883
- Transplant recipients**
- ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 1055
- CERTICOEUR: secondary prevention of skin



cancers in heart transplant recipients (CTR), 88  
 phase II AK study in organ transplant patients (CTR), 1055  
**TUMORAPA 1:** efficacy of rapamycin in secondary prevention of skin cancers in kidney transplant recipients (CTR), 88  
**Treanda.** See Bendamustine HCl intravenous infusion  
**Tretinoin**  
 acne quality of life and patient satisfaction after treatment with tretinoin pump, 1080  
 dapsone gel and tretinoin gel versus tretinoin gel monotherapy for facial acne (CTR), 421  
 efficacy and safety of two topical combination acne regimens, 624  
 safety and efficacy of clindamycin phosphate and tretinoin gel for rosacea (CTR), 421, 597  
 Spear Dermatology Products introduces Refissa™ tretinoin cream (PP), 884  
 tolerability of clindamycin/tretinoin gel versus tretinoin microsphere gel and adapalene gel for acne, 383  
 tretinoin microsphere gel pump versus tazarotene cream for facial acne, 650  
**Tri-Luma® Cream,** for hyperpigmentation (NVR), 879  
**Triamcinolone**  
 adrenal function and use of intralesional triamcinolone acetonide in alopecia areata (CTR), 685, 886  
 intralesional, for alopecia areata (CTR), 196  
 intralesional steroid injections for alopecia areata, 909  
 intramuscular (CR), 580  
 linear hypopigmentation and cutaneous atrophy after intra-articular injections for de Quervain's tendonitis (CR), 492  
 skin concentrations following topical versus oral steroid treatment, 1076  
 topical, 1093  
**Trichloroacetic acid,** versus Jessner's solution for melasma (CTR), 425, 686, 887  
**Trimethoprim-sulfamethoxazole,** antibiotic selection for MRSA (CR), 281  
**Turmeric,** s5 (June)  
**U**  
**U0279,** and injectable biologic combination therapy for psoriasis (CTR), 686, 888, 963, 1057  
**Ultraviolet recall dermatitis,** tamoxifen-induced (CR), 761  
**Ultraviolet (UV) radiation exposure**  
 coal tar plus narrow-band UVB light for psoriasis, 351  
 cutaneous chronic graft versus host disease in treatment with psoralen plus UVA-bath photochemotherapy (CR), 1027  
 Daavlin and UVA1 phototherapy cabinet (PP), 310  
 hand NB-UVB versus Excilite treatment in vitiligo after minigrafting on dorsal hands (CTR), 197  
 narrowband UVB and etanercept for psoriasis (PP), 91  
 pityriasis rubra pilaris sensitive to narrow band UVB light therapy (CR), 270  
 topical perillyl alcohol for sun damaged skin and AK (CTR), 195, 885, 1055  
**Urticaria, chronic**  
 contact allergies in patients with (CTR), 889  
 desloratadine with levocetirizine for (CTR), 90, 601  
 levocetirizine for, 243  
 omalizumab in adults who exhibit IgE against thyroperoxidase (CTR), 90  
 omalizumab in patients who remain symptomatic with antihistamine treatment (CTR), 601, 890

safety and efficacy of abatacept after inadequate response to antihistamine therapy (CTR), 601  
 treatment of (NVR), 1043  
 vitamin D levels in patients with angioedema and (CTR), 889  
**Ustekinumab**  
 biologic survival, 329  
 clinical update on T-cell modulators and investigational agents for psoriasis, 230  
 FDA approves Stelara for psoriasis (PP), 1151  
 management of psoriasis in the age of biologics, s2 (September), s5 (September)

## V

**Vaccines,** against *Propionibacterium acnes*, 615  
**Valacyclovir,** versus FV-100 in herpes zoster (CTR), 785, 1056  
**Vancomycin,** antibiotic selection for MRSA (CR), 281  
**Verruca plantaris,** interferon-2a for (PP), 193  
**Verruca vulgaris,** treatment with *Candida* antigen in a patient with HIV (CR), 268  
**Vibativ™.** See Telavancin  
**Vitamin C,** s10 (June)  
**Vitamin D**  
 in patients with chronic urticaria and angioedema (CTR), 889  
 supplementation in childhood atopic dermatitis (CTR), 963  
**Vitamin D modulators**  
 calcitriol 3 µg/g ointment for psoriasis, s17 (August)  
 in adolescents (CTR), 782  
 efficacy and safety of, s9 (August)  
 introduction to supplement on, s3 (August)  
 optimizing therapy with, s23 (August)  
 FDA approval for Vectical (PP), 497  
 role in the therapy of psoriasis, s4 (August)  
 topical calcipotriol for AK, 451  
**Vitamin E**  
 and fluconazole for yellow nail syndrome (CR), 276  
 natural vitamin E tocotrienol for treatment of surgical scars (CTR), 783  
**Vitamin K oxide gel,** in resolution of postprocedural purpura, 1020  
**Vitiligo**  
 ALA PDT in acne, photoaging and, 562  
 hand NB-UVB versus Excilite treatment in vitiligo after minigrafting on dorsal hands (CTR), 197  
 topical prostaglandin E2 for (PP), 91  
**Vorinostat,** therapies for cutaneous T-cell lymphoma (NVR), 1143  
**Vulvar SCC,** erlotinib for (CTR), 313

## W

**Warts**  
 beyond a decade of 5% imiquimod topical therapy, 467  
 interferon-2a for verruca plantaris (PP), 193  
 treatment of verruca vulgaris with *Candida* antigen in patient with HIV (CR), 268  
**Washington Update (WU),** 891  
**Wound closure**  
 FDA marketing clearance for SurgiSeal (PP), 193  
 linear closure for nasal defects after Mohs micrographic surgery, 23  
 rapid absorbing gut suture versus 2-octylethylcyanoacrylate tissue adhesives in epidermal closure of linear repairs, 115  
**Wound healing**  
 FDA clearance for Microcyn (PP), 681  
 nitric oxide in (NVR), 586

Regenecare® wound gel for rash in patients receiving cetuximab or other epidermal growth factor receptor inhibitor therapy for cancer (CTR), 1054

**Wound packing,** after superficial skin abscess drainage (CTR), 503

## Wrinkles

Belotero® Balance PMA filing accepted (PP), 1051  
 botulinum toxin A for upper facial rhytids, patient perception of treatment outcomes, 924  
 Coapt Systems launches Hydrelle™ (PP), 1051  
 Efudex and rhytids (PP), 883  
 FDA approves poly-L-lactic acid for nasolabial folds (PP), 959  
 high-frequency radiowave system granted FDA clearance (PP), 959  
 hyaluronic acid needle-free injection for damaged and wrinkled skin (CTR), 312  
 nasolabial fold filler study for people of color (CTR), 889  
 Restylane and Perlane in correction of perioral wrinkles (CTR), 1056  
 safety and effectiveness of Belotero® in subjects with Fitzpatrick phototypes V and VI (CTR), 888, 963  
 safety and efficacy of RT001 for lateral canthal lines (CTR), 1056  
 skin rejuvenation and wrinkle reduction using a fractional radiofrequency system, 259  
 twelve-month labeling approval for Evolve (PP), 960

## X

**Xolair®.** See Omalizumab  
**Xyzal®.** See Levocetirizine

## Y

**YAZ.** See Drospirenone and ethinyl estradiol  
**Yellow nail syndrome,** fluconazole and alpha-tocopherol for (CR), 276

## Z

**Zanolimumab,** therapies for cutaneous T-cell lymphoma (NVR), 1143  
**ZD 1839.** See Gefitinib  
**Zinc,** for herpes simplex labialis (CTR), 313, 600